https://trial.medpath.com/news/trifluridine-tipiracil-shows-significant-dfs-improvement-in-resected-stage-iv-colorectal-cancer-patients 2025-01-25T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trifluridine-tipiracil-shows-significant-dfs-improvement-in-resected-stage-iv-colorectal-cancer-patients 2025-01-25T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cadonilimab-chemo-combo-achieves-37-complete-response-in-advanced-rectal-cancer-trial 2025-01-25T22:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cadonilimab-chemo-combo-achieves-37-complete-response-in-advanced-rectal-cancer-trial 2025-01-25T22:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-of-keytruda-before-surgery-shows-promise-in-early-stage-dmmr-colon-cancer 2025-01-25T22:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-of-keytruda-before-surgery-shows-promise-in-early-stage-dmmr-colon-cancer 2025-01-25T22:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/nalirifox-shows-promising-survival-advantage-over-folfirinox-in-metastatic-pancreatic-cancer-real-world-analysis 2025-01-25T22:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nalirifox-shows-promising-survival-advantage-over-folfirinox-in-metastatic-pancreatic-cancer-real-world-analysis 2025-01-25T22:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/bevacizumab-benefits-in-colorectal-cancer-limited-to-two-year-window-new-analysis-reveals 2025-01-25T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bevacizumab-benefits-in-colorectal-cancer-limited-to-two-year-window-new-analysis-reveals 2025-01-25T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-plans-major-clinical-trial-expansion-in-philippines 2025-01-25T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-plans-major-clinical-trial-expansion-in-philippines 2025-01-25T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-study-cancer-drug-ebc-46-shows-breakthrough-potential-for-hiv-eradication 2025-01-25T22:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-study-cancer-drug-ebc-46-shows-breakthrough-potential-for-hiv-eradication 2025-01-25T22:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-opdivo-yervoy-combination-shows-38-reduction-in-colorectal-cancer-relapse-risk 2025-01-25T20:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-opdivo-yervoy-combination-shows-38-reduction-in-colorectal-cancer-relapse-risk 2025-01-25T20:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/novel-peptide-certepetide-shows-mixed-results-when-added-to-standard-pancreatic-cancer-treatment 2025-01-25T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-peptide-certepetide-shows-mixed-results-when-added-to-standard-pancreatic-cancer-treatment 2025-01-25T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-reduces-cancer-recurrence-by-over-50-in-pi3k-mutated-colorectal-cancer-alascca-trial-shows 2025-01-25T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspirin-reduces-cancer-recurrence-by-over-50-in-pi3k-mutated-colorectal-cancer-alascca-trial-shows 2025-01-25T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/dose-reductions-in-nalirifox-regimen-show-no-negative-impact-on-pancreatic-cancer-survival 2025-01-25T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dose-reductions-in-nalirifox-regimen-show-no-negative-impact-on-pancreatic-cancer-survival 2025-01-25T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/biosimilars-prove-safe-and-effective-for-pediatric-ibd-treatment-in-large-french-study 2025-01-25T19:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosimilars-prove-safe-and-effective-for-pediatric-ibd-treatment-in-large-french-study 2025-01-25T19:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/opdivo-yervoy-combination-shows-superior-survival-benefits-in-advanced-liver-cancer-trial 2025-01-25T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opdivo-yervoy-combination-shows-superior-survival-benefits-in-advanced-liver-cancer-trial 2025-01-25T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/lixumistat-shows-promising-results-in-phase-1b-pancreatic-cancer-trial 2025-01-25T17:01:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixumistat-shows-promising-results-in-phase-1b-pancreatic-cancer-trial 2025-01-25T17:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-amycretin-shows-22-weight-loss-in-phase-1b-2a-obesity-trial 2025-01-25T16:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-amycretin-shows-22-weight-loss-in-phase-1b-2a-obesity-trial 2025-01-25T16:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/anavex-s-blarcamesine-shows-promising-results-in-alzheimer-s-disease-maa-submission-advances-eu-strategy 2025-01-25T16:03:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anavex-s-blarcamesine-shows-promising-results-in-alzheimer-s-disease-maa-submission-advances-eu-strategy 2025-01-25T16:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-lapis-trial-pamrevlumab-chemotherapy-combination-shows-no-survival-benefit-in-advanced-pancreatic-cancer 2025-01-25T16:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-lapis-trial-pamrevlumab-chemotherapy-combination-shows-no-survival-benefit-in-advanced-pancreatic-cancer 2025-01-25T16:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/zoldonrasib-shows-promising-safety-and-efficacy-in-kras-g12d-mutated-pancreatic-cancer-trial 2025-01-25T16:02:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoldonrasib-shows-promising-safety-and-efficacy-in-kras-g12d-mutated-pancreatic-cancer-trial 2025-01-25T16:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oral-rdrp-inhibitor-shen26-shows-promise-in-phase-ii-covid-19-trial 2025-01-25T16:02:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-oral-rdrp-inhibitor-shen26-shows-promise-in-phase-ii-covid-19-trial 2025-01-25T16:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-status-predicts-celecoxib-benefit-in-stage-iii-colon-cancer-phase-3-trial-shows 2025-01-25T16:02:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-status-predicts-celecoxib-benefit-in-stage-iii-colon-cancer-phase-3-trial-shows 2025-01-25T16:02:05+00:00 hourly 0.9 https://trial.medpath.com/news/novel-low-dose-copper-iud-shows-promise-in-phase-3-trial-with-99-efficacy-rate 2025-01-25T16:01:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-low-dose-copper-iud-shows-promise-in-phase-3-trial-with-99-efficacy-rate 2025-01-25T16:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-accelerate-trial-chemoradiation-addition-shows-no-rfs-benefit-in-resected-gallbladder-cancer 2025-01-25T16:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-accelerate-trial-chemoradiation-addition-shows-no-rfs-benefit-in-resected-gallbladder-cancer 2025-01-25T16:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/pantheon-vision-advances-development-of-bioengineered-corneal-implants-following-fda-meeting 2025-01-25T15:52:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pantheon-vision-advances-development-of-bioengineered-corneal-implants-following-fda-meeting 2025-01-25T15:52:38+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-secures-126m-in-first-us-biotech-ipo-of-2025-advancing-novel-cancer-therapies 2025-01-25T15:52:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-secures-126m-in-first-us-biotech-ipo-of-2025-advancing-novel-cancer-therapies 2025-01-25T15:52:20+00:00 hourly 0.9 https://trial.medpath.com/news/faricimab-rechallenge-linked-to-severe-vision-loss-in-patients-with-prior-inflammation 2025-01-25T15:52:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faricimab-rechallenge-linked-to-severe-vision-loss-in-patients-with-prior-inflammation 2025-01-25T15:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-predicts-celecoxib-s-effectiveness-in-preventing-colon-cancer-recurrence 2025-01-25T15:51:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-predicts-celecoxib-s-effectiveness-in-preventing-colon-cancer-recurrence 2025-01-25T15:51:44+00:00 hourly 0.9 https://trial.medpath.com/news/digoxin-shows-promise-in-disrupting-cancer-cell-clusters-opening-new-path-for-metastasis-prevention 2025-01-25T15:51:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digoxin-shows-promise-in-disrupting-cancer-cell-clusters-opening-new-path-for-metastasis-prevention 2025-01-25T15:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/novel-biotherapeutic-ve303-shows-80-reduction-in-recurrent-c-difficile-infection-risk 2025-01-25T15:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-biotherapeutic-ve303-shows-80-reduction-in-recurrent-c-difficile-infection-risk 2025-01-25T15:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/checkpoint-inhibitor-use-surges-following-fda-approval-for-gastroesophageal-cancer-treatment 2025-01-25T15:50:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/checkpoint-inhibitor-use-surges-following-fda-approval-for-gastroesophageal-cancer-treatment 2025-01-25T15:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/reithera-and-sillajen-partner-to-advance-novel-anticancer-virus-platform-for-clinical-development 2025-01-25T15:50:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reithera-and-sillajen-partner-to-advance-novel-anticancer-virus-platform-for-clinical-development 2025-01-25T15:50:41+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-eisai-s-keytruda-lenvima-combo-shows-mixed-phase-3-results-in-gastric-cancer 2025-01-25T15:50:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-eisai-s-keytruda-lenvima-combo-shows-mixed-phase-3-results-in-gastric-cancer 2025-01-25T15:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-shows-palliative-care-benefits-young-colorectal-cancer-patients-at-end-of-life 2025-01-25T13:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-shows-palliative-care-benefits-young-colorectal-cancer-patients-at-end-of-life 2025-01-25T13:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/attovia-therapeutics-initiates-phase-1-trial-of-novel-anti-il-31-therapy-for-chronic-pruritus 2025-01-25T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attovia-therapeutics-initiates-phase-1-trial-of-novel-anti-il-31-therapy-for-chronic-pruritus 2025-01-25T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gender-based-study-reveals-distinct-ptsd-symptom-patterns-in-early-trauma-response 2025-01-25T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gender-based-study-reveals-distinct-ptsd-symptom-patterns-in-early-trauma-response 2025-01-25T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiotherapy-shows-survival-benefits-for-elderly-patients-with-early-stage-triple-negative-breast-cancer 2025-01-25T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiotherapy-shows-survival-benefits-for-elderly-patients-with-early-stage-triple-negative-breast-cancer 2025-01-25T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-no-direct-causal-link-between-osteoarthritis-and-cognitive-decline-depression-may-play-key-role 2025-01-25T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-no-direct-causal-link-between-osteoarthritis-and-cognitive-decline-depression-may-play-key-role 2025-01-25T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amrita-school-of-ayurveda-study-shows-promise-of-cannabis-based-treatment-for-menstrual-pain 2025-01-25T02:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amrita-school-of-ayurveda-study-shows-promise-of-cannabis-based-treatment-for-menstrual-pain 2025-01-25T02:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/flash-radiotherapy-ultra-fast-cancer-treatment-shows-promise-as-radiation-alternative 2025-01-25T00:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flash-radiotherapy-ultra-fast-cancer-treatment-shows-promise-as-radiation-alternative 2025-01-25T00:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-actemra-shows-promise-in-reducing-covid-19-ventilation-risk-among-minority-patients 2025-01-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-actemra-shows-promise-in-reducing-covid-19-ventilation-risk-among-minority-patients 2025-01-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-reports-breakthrough-in-next-generation-cgm-technology-with-promising-pre-pivotal-trial-results 2025-01-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-reports-breakthrough-in-next-generation-cgm-technology-with-promising-pre-pivotal-trial-results 2025-01-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/musc-launches-clinical-trial-for-revolutionary-wire-free-cochlear-implant-system 2025-01-24T23:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/musc-launches-clinical-trial-for-revolutionary-wire-free-cochlear-implant-system 2025-01-24T23:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/lonsurf-plus-bevacizumab-shows-improved-survival-in-real-world-metastatic-colorectal-cancer-study 2025-01-24T22:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonsurf-plus-bevacizumab-shows-improved-survival-in-real-world-metastatic-colorectal-cancer-study 2025-01-24T22:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-clinical-trial-diversity-guidelines-amid-policy-shift 2025-01-24T22:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-clinical-trial-diversity-guidelines-amid-policy-shift 2025-01-24T22:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-halts-capital-raising-plans-following-positive-ms-biomarker-discovery 2025-01-24T19:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiziana-life-sciences-halts-capital-raising-plans-following-positive-ms-biomarker-discovery 2025-01-24T19:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/perspective-therapeutics-reports-positive-safety-and-early-efficacy-data-in-net-cancer-trial 2025-01-24T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perspective-therapeutics-reports-positive-safety-and-early-efficacy-data-in-net-cancer-trial 2025-01-24T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/reduced-dexamethasone-dosing-shows-comparable-survival-outcomes-in-multiple-myeloma-treatment 2025-01-24T16:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reduced-dexamethasone-dosing-shows-comparable-survival-outcomes-in-multiple-myeloma-treatment 2025-01-24T16:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-2-keymaker-u02-trial-pembrolizumab-shows-manageable-safety-profile-in-stage-iiib-d-melanoma 2025-01-24T16:04:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-2-keymaker-u02-trial-pembrolizumab-shows-manageable-safety-profile-in-stage-iiib-d-melanoma 2025-01-24T16:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-shows-79-sensitivity-in-colorectal-cancer-detection-preempt-crc-trial-reports 2025-01-24T15:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-shows-79-sensitivity-in-colorectal-cancer-detection-preempt-crc-trial-reports 2025-01-24T15:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/alterity-s-ath434-phase-2-trial-in-early-stage-msa-completes-with-results-expected-february-2025 2025-01-24T15:01:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alterity-s-ath434-phase-2-trial-in-early-stage-msa-completes-with-results-expected-february-2025 2025-01-24T15:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/unc-researchers-lead-groundbreaking-hiv-clinical-trials-in-vietnam 2025-01-24T14:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unc-researchers-lead-groundbreaking-hiv-clinical-trials-in-vietnam 2025-01-24T14:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/ema-validates-marketing-authorization-application-for-mavorixafor-in-whim-syndrome-treatment 2025-01-24T14:01:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-validates-marketing-authorization-application-for-mavorixafor-in-whim-syndrome-treatment 2025-01-24T14:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/china-medical-system-s-mg-k10-advances-in-phase-iii-trials-for-multiple-inflammatory-conditions 2025-01-24T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-medical-system-s-mg-k10-advances-in-phase-iii-trials-for-multiple-inflammatory-conditions 2025-01-24T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-novel-amycretin-shows-22-weight-reduction-in-early-stage-trial 2025-01-24T13:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-novel-amycretin-shows-22-weight-reduction-in-early-stage-trial 2025-01-24T13:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hydrogel-based-immunotherapy-shows-promise-in-triple-negative-breast-cancer-treatment 2025-01-24T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hydrogel-based-immunotherapy-shows-promise-in-triple-negative-breast-cancer-treatment 2025-01-24T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/prophylactic-cardiac-treatment-shows-54-lower-mortality-risk-in-duchenne-muscular-dystrophy-patients 2025-01-24T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prophylactic-cardiac-treatment-shows-54-lower-mortality-risk-in-duchenne-muscular-dystrophy-patients 2025-01-24T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lenacapavir-shows-promising-results-in-phase-3-trial-for-multidrug-resistant-hiv-1 2025-01-24T11:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenacapavir-shows-promising-results-in-phase-3-trial-for-multidrug-resistant-hiv-1 2025-01-24T11:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-five-key-mechanisms-linking-alcohol-consumption-to-cancer-development 2025-01-24T11:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-research-reveals-five-key-mechanisms-linking-alcohol-consumption-to-cancer-development 2025-01-24T11:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/onconic-s-jaqbo-shows-100-efficacy-in-phase-3-gastric-ulcer-trial-seeks-expanded-indication 2025-01-24T11:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onconic-s-jaqbo-shows-100-efficacy-in-phase-3-gastric-ulcer-trial-seeks-expanded-indication 2025-01-24T11:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-novel-pain-drug-halneuron-r-drives-368-stock-rally-amid-phase-2b-trial-launch 2025-01-24T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogwood-therapeutics-novel-pain-drug-halneuron-r-drives-368-stock-rally-amid-phase-2b-trial-launch 2025-01-24T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/prehabilitation-before-surgery-significantly-reduces-complications-and-hospital-stays-study-shows 2025-01-24T11:01:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prehabilitation-before-surgery-significantly-reduces-complications-and-hospital-stays-study-shows 2025-01-24T11:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/vigil-neuroscience-reports-promising-early-stage-data-for-novel-alzheimer-s-drug 2025-01-24T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vigil-neuroscience-reports-promising-early-stage-data-for-novel-alzheimer-s-drug 2025-01-24T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-full-spectrum-cannabis-based-drug-for-autism-enters-clinical-trials-with-promising-phase-1-results 2025-01-24T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-full-spectrum-cannabis-based-drug-for-autism-enters-clinical-trials-with-promising-phase-1-results 2025-01-24T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-evatm-first-automated-programming-platform-for-spinal-cord-stimulation 2025-01-24T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-evatm-first-automated-programming-platform-for-spinal-cord-stimulation 2025-01-24T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-hpv-vaccine-shows-promise-in-eliminating-precancerous-cervical-lesions 2025-01-24T10:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapeutic-hpv-vaccine-shows-promise-in-eliminating-precancerous-cervical-lesions 2025-01-24T10:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-s-narrative-medicine-program-reveals-impact-of-long-acting-hiv-treatments-through-patient-stories 2025-01-24T09:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-jude-s-narrative-medicine-program-reveals-impact-of-long-acting-hiv-treatments-through-patient-stories 2025-01-24T09:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-zero-hiv-transmission-risk-in-art-treated-couples 2025-01-24T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-zero-hiv-transmission-risk-in-art-treated-couples 2025-01-24T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/pbm-reform-bill-shows-strong-promise-for-2024-passage-aims-to-boost-drug-pricing-transparency 2025-01-24T09:01:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pbm-reform-bill-shows-strong-promise-for-2024-passage-aims-to-boost-drug-pricing-transparency 2025-01-24T09:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/novel-non-invasive-biomarkers-essential-for-advancing-pancreatic-cancer-diagnostics-expert-emphasizes 2025-01-24T08:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-non-invasive-biomarkers-essential-for-advancing-pancreatic-cancer-diagnostics-expert-emphasizes 2025-01-24T08:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-files-for-100m-ipo-to-advance-novel-hyperphagia-treatment 2025-01-24T08:47:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aardvark-therapeutics-files-for-100m-ipo-to-advance-novel-hyperphagia-treatment 2025-01-24T08:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/larimar-therapeutics-advances-pediatric-study-of-nomlabofusp-for-friedreich-s-ataxia 2025-01-24T08:31:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larimar-therapeutics-advances-pediatric-study-of-nomlabofusp-for-friedreich-s-ataxia 2025-01-24T08:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/five-key-trends-reshaping-pharmacy-benefits-landscape-in-2025-biosimilars-glp-1s-lead-market-evolution 2025-01-24T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-key-trends-reshaping-pharmacy-benefits-landscape-in-2025-biosimilars-glp-1s-lead-market-evolution 2025-01-24T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/basal-cell-carcinoma-market-set-to-reach-9-7-billion-by-2035-driven-by-early-detection-and-novel-therapies 2025-01-24T07:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basal-cell-carcinoma-market-set-to-reach-9-7-billion-by-2035-driven-by-early-detection-and-novel-therapies 2025-01-24T07:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-emerge-as-critical-partners-in-multiple-sclerosis-b-cell-therapy-management 2025-01-24T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-emerge-as-critical-partners-in-multiple-sclerosis-b-cell-therapy-management 2025-01-24T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/deep-response-to-tislelizumab-chemotherapy-combination-correlates-with-extended-survival-in-advanced-esophageal-cancer 2025-01-24T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-response-to-tislelizumab-chemotherapy-combination-correlates-with-extended-survival-in-advanced-esophageal-cancer 2025-01-24T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-inceptiv-closed-loop-scs-shows-strong-12-month-pain-relief-data 2025-01-24T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-inceptiv-closed-loop-scs-shows-strong-12-month-pain-relief-data 2025-01-24T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-to-sanofi-for-manufacturing-violations-places-clinical-hold-on-atara-s-immunotherapies 2025-01-24T07:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-to-sanofi-for-manufacturing-violations-places-clinical-hold-on-atara-s-immunotherapies 2025-01-24T07:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/pain-neuroscience-education-shows-promise-in-reducing-post-operative-pain-after-laparoscopic-hernia-repair 2025-01-24T07:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pain-neuroscience-education-shows-promise-in-reducing-post-operative-pain-after-laparoscopic-hernia-repair 2025-01-24T07:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/aap-implantate-ag-achieves-6-sales-growth-in-2024-reports-progress-in-antibacterial-implants-study 2025-01-24T07:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aap-implantate-ag-achieves-6-sales-growth-in-2024-reports-progress-in-antibacterial-implants-study 2025-01-24T07:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/allergan-aesthetics-launches-aa-signature-program-to-transform-personalized-aesthetic-treatments 2025-01-24T06:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergan-aesthetics-launches-aa-signature-program-to-transform-personalized-aesthetic-treatments 2025-01-24T06:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/high-out-of-pocket-costs-linked-to-lower-cardiac-rehabilitation-adherence-study-finds 2025-01-24T06:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-out-of-pocket-costs-linked-to-lower-cardiac-rehabilitation-adherence-study-finds 2025-01-24T06:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-medical-initiates-global-phase-iii-trial-for-head-and-neck-cancer-treatment 2025-01-24T04:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakuten-medical-initiates-global-phase-iii-trial-for-head-and-neck-cancer-treatment 2025-01-24T04:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-shr-1701-combination-therapy-shows-promise-in-reducing-chemotherapy-induced-myelosuppression-for-gastric-cancer-patients 2025-01-24T04:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-shr-1701-combination-therapy-shows-promise-in-reducing-chemotherapy-induced-myelosuppression-for-gastric-cancer-patients 2025-01-24T04:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-clia-waiver-for-roche-s-rapid-sti-testing-panels-enabling-20-minute-results 2025-01-24T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-clia-waiver-for-roche-s-rapid-sti-testing-panels-enabling-20-minute-results 2025-01-24T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/pfa-technology-dominates-cardiac-rhythm-innovation-in-2024-multiple-companies-achieve-key-milestones 2025-01-24T04:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfa-technology-dominates-cardiac-rhythm-innovation-in-2024-multiple-companies-achieve-key-milestones 2025-01-24T04:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/combination-of-afinitor-and-somatuline-shows-superior-results-in-advanced-gep-net-treatment 2025-01-24T04:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-of-afinitor-and-somatuline-shows-superior-results-in-advanced-gep-net-treatment 2025-01-24T04:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/repatha-safety-data-limited-for-pregnancy-and-breastfeeding-manufacturer-launches-pregnancy-registry 2025-01-24T04:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repatha-safety-data-limited-for-pregnancy-and-breastfeeding-manufacturer-launches-pregnancy-registry 2025-01-24T04:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-industry-faces-pivotal-year-j-p-morgan-conference-signals-key-2025-challenges 2025-01-24T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-industry-faces-pivotal-year-j-p-morgan-conference-signals-key-2025-challenges 2025-01-24T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oximio-expands-ultra-cold-storage-capabilities-amid-growing-clinical-trial-logistics-challenges 2025-01-24T03:25:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oximio-expands-ultra-cold-storage-capabilities-amid-growing-clinical-trial-logistics-challenges 2025-01-24T03:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-commits-570m-investment-to-expand-canadian-operations-and-r-d-hub 2025-01-24T03:21:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-commits-570m-investment-to-expand-canadian-operations-and-r-d-hub 2025-01-24T03:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/promising-results-for-her2-targeted-therapy-in-previously-treated-breast-cancer-patients 2025-01-24T02:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-results-for-her2-targeted-therapy-in-previously-treated-breast-cancer-patients 2025-01-24T02:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/5-year-data-confirms-long-term-survival-benefit-of-nivolumab-chemotherapy-combination-in-advanced-gastric-cancers 2025-01-24T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/5-year-data-confirms-long-term-survival-benefit-of-nivolumab-chemotherapy-combination-in-advanced-gastric-cancers 2025-01-24T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-medical-launches-global-phase-3-trial-combining-photoimmunotherapy-with-pembrolizumab-for-head-and-neck-cancer 2025-01-24T01:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakuten-medical-launches-global-phase-3-trial-combining-photoimmunotherapy-with-pembrolizumab-for-head-and-neck-cancer 2025-01-24T01:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-growing-adoption-of-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma-treatment 2025-01-24T01:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-growing-adoption-of-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma-treatment 2025-01-24T01:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/sglt-2-inhibitor-plus-calorie-restriction-doubles-diabetes-remission-success-in-clinical-trial 2025-01-24T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt-2-inhibitor-plus-calorie-restriction-doubles-diabetes-remission-success-in-clinical-trial 2025-01-24T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-expands-deucrictibant-development-to-acquired-angioedema-following-promising-early-data 2025-01-24T01:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharvaris-expands-deucrictibant-development-to-acquired-angioedema-following-promising-early-data 2025-01-24T01:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-for-dry-amd-treatment-expands-with-70-companies-advancing-novel-therapies 2025-01-24T01:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-for-dry-amd-treatment-expands-with-70-companies-advancing-novel-therapies 2025-01-24T01:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/acc-25-to-feature-groundbreaking-clinical-trials-in-cardiovascular-medicine 2025-01-24T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acc-25-to-feature-groundbreaking-clinical-trials-in-cardiovascular-medicine 2025-01-24T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/medidata-and-tigermed-strengthen-13-year-partnership-to-advance-global-clinical-trial-technology 2025-01-24T01:24:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medidata-and-tigermed-strengthen-13-year-partnership-to-advance-global-clinical-trial-technology 2025-01-24T01:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-clarity-pharmaceuticals-novel-prostate-cancer-imaging-agent 2025-01-24T00:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-clarity-pharmaceuticals-novel-prostate-cancer-imaging-agent 2025-01-24T00:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nsclc-studies-of-2024-laura-empower-lung-1-and-beamion-lung-1-trials-show-promise 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-nsclc-studies-of-2024-laura-empower-lung-1-and-beamion-lung-1-trials-show-promise 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dato-dxd-integration-in-breast-cancer-treatment-raises-questions-about-adc-sequencing-and-safety-profiles 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dato-dxd-integration-in-breast-cancer-treatment-raises-questions-about-adc-sequencing-and-safety-profiles 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-study-reveals-critical-factors-for-successful-dli-treatment-in-relapsed-aml-patients 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-study-reveals-critical-factors-for-successful-dli-treatment-in-relapsed-aml-patients 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/buprenorphine-microdosing-strategy-shows-limited-success-in-fentanyl-users-ucsf-study-finds 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/buprenorphine-microdosing-strategy-shows-limited-success-in-fentanyl-users-ucsf-study-finds 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zeo-scientifix-partners-with-exotropin-to-develop-novel-hair-loss-treatment-solution 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeo-scientifix-partners-with-exotropin-to-develop-novel-hair-loss-treatment-solution 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapy-combination-shows-promise-against-melanoma-and-breast-cancer-metastases 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapy-combination-shows-promise-against-melanoma-and-breast-cancer-metastases 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-limits-gsk-s-xevudy-authorization-due-to-ba-2-variant-concerns 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-limits-gsk-s-xevudy-authorization-due-to-ba-2-variant-concerns 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-s-otx-tki-shows-promise-for-diabetic-retinopathy-phase-3-trial-planned 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-s-otx-tki-shows-promise-for-diabetic-retinopathy-phase-3-trial-planned 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-jardiance-for-chronic-kidney-disease-treatment 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-jardiance-for-chronic-kidney-disease-treatment 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivaltinostat-shows-promise-in-phase-1b-trial-for-metastatic-pancreatic-cancer 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivaltinostat-shows-promise-in-phase-1b-trial-for-metastatic-pancreatic-cancer 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-s-gene-therapy-shows-promise-in-phase-1-heart-failure-trial 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-s-gene-therapy-shows-promise-in-phase-1-heart-failure-trial 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-rexulti-as-breakthrough-treatment-for-alzheimer-s-related-agitation 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-rexulti-as-breakthrough-treatment-for-alzheimer-s-related-agitation 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-advances-novel-inkt-cell-therapy-combination-for-advanced-gastroesophageal-cancer 2025-01-23T22:33:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-advances-novel-inkt-cell-therapy-combination-for-advanced-gastroesophageal-cancer 2025-01-23T22:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapy-combination-trial-launches-for-advanced-gastroesophageal-cancer 2025-01-23T22:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapy-combination-trial-launches-for-advanced-gastroesophageal-cancer 2025-01-23T22:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/camrelizumab-chemotherapy-combination-shows-promising-3-year-survival-in-advanced-gastric-cancer 2025-01-23T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camrelizumab-chemotherapy-combination-shows-promising-3-year-survival-in-advanced-gastric-cancer 2025-01-23T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/diuretic-protocol-enhances-prostate-cancer-detection-in-18f-flotufolastat-pet-ct-imaging 2025-01-23T22:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diuretic-protocol-enhances-prostate-cancer-detection-in-18f-flotufolastat-pet-ct-imaging 2025-01-23T22:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-endorses-phase-3-strategy-for-novel-kras-targeted-cancer-vaccine-eli-002 2025-01-23T22:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-endorses-phase-3-strategy-for-novel-kras-targeted-cancer-vaccine-eli-002 2025-01-23T22:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-reports-successful-pk-study-results-for-novel-sleep-apnea-combination-drug-ihl-42x 2025-01-23T22:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incannex-reports-successful-pk-study-results-for-novel-sleep-apnea-combination-drug-ihl-42x 2025-01-23T22:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/helios-trial-novel-axitinib-implant-shows-promise-in-diabetic-retinopathy-treatment 2025-01-23T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helios-trial-novel-axitinib-implant-shows-promise-in-diabetic-retinopathy-treatment 2025-01-23T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/lapix-therapeutics-initiates-phase-1b-trial-of-novel-oral-immunomodulator-for-rheumatoid-and-psoriatic-arthritis 2025-01-23T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lapix-therapeutics-initiates-phase-1b-trial-of-novel-oral-immunomodulator-for-rheumatoid-and-psoriatic-arthritis 2025-01-23T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-participant-dies-in-bangalore-investigation-underway-at-syngene-international 2025-01-23T22:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-participant-dies-in-bangalore-investigation-underway-at-syngene-international 2025-01-23T22:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/drcr-retina-network-s-20-year-legacy-reshapes-diabetic-eye-disease-management 2025-01-23T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drcr-retina-network-s-20-year-legacy-reshapes-diabetic-eye-disease-management 2025-01-23T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-transplant-shows-promise-for-young-adults-with-severe-sickle-cell-disease 2025-01-23T22:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-transplant-shows-promise-for-young-adults-with-severe-sickle-cell-disease 2025-01-23T22:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/inhibikase-therapeutics-secures-275m-financing-advances-ikt-001pro-for-pulmonary-arterial-hypertension 2025-01-23T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibikase-therapeutics-secures-275m-financing-advances-ikt-001pro-for-pulmonary-arterial-hypertension 2025-01-23T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-s-lx9211-phase-2b-trial-for-diabetic-neuropathic-pain-completes-enrollment-ahead-of-schedule 2025-01-23T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-s-lx9211-phase-2b-trial-for-diabetic-neuropathic-pain-completes-enrollment-ahead-of-schedule 2025-01-23T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flot-chemotherapy-significantly-extends-survival-in-resectable-esophageal-cancer-patients 2025-01-23T20:01:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flot-chemotherapy-significantly-extends-survival-in-resectable-esophageal-cancer-patients 2025-01-23T20:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/evorpacept-shows-promising-results-in-phase-2-trial-for-her2-positive-gastric-cancer 2025-01-23T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evorpacept-shows-promising-results-in-phase-2-trial-for-her2-positive-gastric-cancer 2025-01-23T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oral-trem2-agonist-shows-promise-in-early-alzheimer-s-trial-advances-to-phase-ii 2025-01-23T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-oral-trem2-agonist-shows-promise-in-early-alzheimer-s-trial-advances-to-phase-ii 2025-01-23T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/pallas-trial-palbociclib-shows-no-benefit-in-stage-iia-iii-hr-breast-cancer-treatment 2025-01-23T19:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pallas-trial-palbociclib-shows-no-benefit-in-stage-iia-iii-hr-breast-cancer-treatment 2025-01-23T19:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/exact-sciences-oncodetect-mrd-test-shows-high-sensitivity-in-late-stage-colon-cancer-trial 2025-01-23T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exact-sciences-oncodetect-mrd-test-shows-high-sensitivity-in-late-stage-colon-cancer-trial 2025-01-23T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-novel-hepatitis-delta-treatment-brelovitug 2025-01-23T19:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-status-to-novel-hepatitis-delta-treatment-brelovitug 2025-01-23T19:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/ketamine-shows-promise-in-treating-parkinson-s-related-dyskinesia-by-restoring-motor-control 2025-01-23T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketamine-shows-promise-in-treating-parkinson-s-related-dyskinesia-by-restoring-motor-control 2025-01-23T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-s-fostamatinib-enters-phase-i-trial-for-sickle-cell-disease-treatment 2025-01-23T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-s-fostamatinib-enters-phase-i-trial-for-sickle-cell-disease-treatment 2025-01-23T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-novel-pompe-disease-combination-therapy-trial 2025-01-23T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-novel-pompe-disease-combination-therapy-trial 2025-01-23T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/exuma-biotech-reports-promising-phase-1-results-for-novel-her2-targeted-car-t-therapy-in-solid-tumors 2025-01-23T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exuma-biotech-reports-promising-phase-1-results-for-novel-her2-targeted-car-t-therapy-in-solid-tumors 2025-01-23T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/csl-s-breakthrough-new-monthly-injectable-andembry-approved-for-hereditary-angioedema 2025-01-23T19:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-s-breakthrough-new-monthly-injectable-andembry-approved-for-hereditary-angioedema 2025-01-23T19:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/tris-pharma-s-cebranopadol-shows-promise-in-phase-3-acute-pain-trial 2025-01-23T18:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tris-pharma-s-cebranopadol-shows-promise-in-phase-3-acute-pain-trial 2025-01-23T18:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-zai-lab-s-novel-dll3-targeting-therapy-for-small-cell-lung-cancer 2025-01-23T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-zai-lab-s-novel-dll3-targeting-therapy-for-small-cell-lung-cancer 2025-01-23T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/ashibio-launches-phase-2-3-trial-of-novel-fop-treatment-targeting-mmp-9-enzyme 2025-01-23T16:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ashibio-launches-phase-2-3-trial-of-novel-fop-treatment-targeting-mmp-9-enzyme 2025-01-23T16:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/evorpacept-shows-breakthrough-49-response-rate-in-her2-positive-gastric-cancer-trial 2025-01-23T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evorpacept-shows-breakthrough-49-response-rate-in-her2-positive-gastric-cancer-trial 2025-01-23T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-accept-biogen-s-application-for-higher-dose-spinraza-amid-research-restructuring 2025-01-23T16:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-ema-accept-biogen-s-application-for-higher-dose-spinraza-amid-research-restructuring 2025-01-23T16:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/eur38m-european-study-launches-to-prevent-crohn-s-disease-using-novel-biomarker-approach 2025-01-23T16:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eur38m-european-study-launches-to-prevent-crohn-s-disease-using-novel-biomarker-approach 2025-01-23T16:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-period-for-elamipretide-in-barth-syndrome-treatment 2025-01-23T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-period-for-elamipretide-in-barth-syndrome-treatment 2025-01-23T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-amneal-s-generic-versions-of-alzheimer-s-and-tsc-medications 2025-01-23T16:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-amneal-s-generic-versions-of-alzheimer-s-and-tsc-medications 2025-01-23T16:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/ampligen-shows-promise-in-phase-2-trial-for-long-covid-related-fatigue 2025-01-23T16:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ampligen-shows-promise-in-phase-2-trial-for-long-covid-related-fatigue 2025-01-23T16:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-research-uk-partners-with-cytovation-to-launch-phase-2-trial-for-rare-adrenal-cancer-drug 2025-01-23T16:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-research-uk-partners-with-cytovation-to-launch-phase-2-trial-for-rare-adrenal-cancer-drug 2025-01-23T16:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-awards-dual-designations-to-tikun-s-novel-familial-dysautonomia-treatments 2025-01-23T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-awards-dual-designations-to-tikun-s-novel-familial-dysautonomia-treatments 2025-01-23T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/persephone-biosciences-launches-artemis-trial-to-test-novel-infant-synbiotic-treatment 2025-01-23T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persephone-biosciences-launches-artemis-trial-to-test-novel-infant-synbiotic-treatment 2025-01-23T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/xilio-therapeutics-reports-promising-phase-ii-results-for-vilastobart-combination-in-colorectal-cancer 2025-01-23T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xilio-therapeutics-reports-promising-phase-ii-results-for-vilastobart-combination-in-colorectal-cancer 2025-01-23T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/arctic-vision-secures-regulatory-approval-for-novel-suprachoroidal-ume-treatment-in-australia-and-singapore 2025-01-23T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arctic-vision-secures-regulatory-approval-for-novel-suprachoroidal-ume-treatment-in-australia-and-singapore 2025-01-23T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-to-limit-glp-1-coverage-for-state-employees-saving-17-million-annually 2025-01-23T12:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-to-limit-glp-1-coverage-for-state-employees-saving-17-million-annually 2025-01-23T12:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/spring-summer-birth-and-cd247-gene-variant-linked-to-higher-celiac-disease-risk-in-large-scale-study 2025-01-23T10:46:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spring-summer-birth-and-cd247-gene-variant-linked-to-higher-celiac-disease-risk-in-large-scale-study 2025-01-23T10:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/belimumab-shows-superior-outcomes-in-pediatric-lupus-nephritis-treatment-study 2025-01-23T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belimumab-shows-superior-outcomes-in-pediatric-lupus-nephritis-treatment-study 2025-01-23T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-c-the-signs-shows-93-8-sensitivity-in-early-colorectal-cancer-detection 2025-01-23T10:20:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-c-the-signs-shows-93-8-sensitivity-in-early-colorectal-cancer-detection 2025-01-23T10:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-landscape-of-her2-directed-tumor-agnostic-therapies-shows-promise-in-cancer-treatment 2025-01-23T10:18:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-landscape-of-her2-directed-tumor-agnostic-therapies-shows-promise-in-cancer-treatment 2025-01-23T10:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-increased-sjogren-s-syndrome-risk-in-psoriasis-patients-suggesting-shared-immune-mechanisms 2025-01-23T09:53:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-increased-sjogren-s-syndrome-risk-in-psoriasis-patients-suggesting-shared-immune-mechanisms 2025-01-23T09:53:46+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-and-ophthalmology-biosimilars-achieve-81-market-share-in-latest-samsung-bioepis-report 2025-01-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-and-ophthalmology-biosimilars-achieve-81-market-share-in-latest-samsung-bioepis-report 2025-01-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-report-establishes-new-diagnostic-framework-for-clinical-obesity-moving-beyond-bmi 2025-01-23T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-report-establishes-new-diagnostic-framework-for-clinical-obesity-moving-beyond-bmi 2025-01-23T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-launches-first-decentralized-clinical-trial-program-with-3-3m-investment 2025-01-23T07:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-launches-first-decentralized-clinical-trial-program-with-3-3m-investment 2025-01-23T07:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-daiichi-sankyo-s-dato-dxd-for-breast-cancer-expanding-treatment-options 2025-01-23T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-daiichi-sankyo-s-dato-dxd-for-breast-cancer-expanding-treatment-options 2025-01-23T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-genomic-testing-in-cancer-care-balancing-urgency-and-clinical-impact 2025-01-23T06:00:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-genomic-testing-in-cancer-care-balancing-urgency-and-clinical-impact 2025-01-23T06:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-biosciences-liver-cancer-triplet-therapy-shows-promise-in-phase-2-study 2025-01-23T05:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-biosciences-liver-cancer-triplet-therapy-shows-promise-in-phase-2-study 2025-01-23T05:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-mandates-boxed-warning-for-copaxone-and-glatopa-over-anaphylaxis-risk 2025-01-23T05:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-mandates-boxed-warning-for-copaxone-and-glatopa-over-anaphylaxis-risk 2025-01-23T05:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-showcases-latest-aesthetic-portfolio-data-at-imcas-2025-highlighting-relfydess-and-restylane-advances 2025-01-23T04:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-showcases-latest-aesthetic-portfolio-data-at-imcas-2025-highlighting-relfydess-and-restylane-advances 2025-01-23T04:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/piper-sandler-initiates-buy-rating-on-bright-minds-bmb-101-for-drug-resistant-epilepsy-treatment 2025-01-23T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piper-sandler-initiates-buy-rating-on-bright-minds-bmb-101-for-drug-resistant-epilepsy-treatment 2025-01-23T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-ceo-outlines-strategy-for-attruby-launch-in-attr-cm-market 2025-01-23T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-ceo-outlines-strategy-for-attruby-launch-in-attr-cm-market 2025-01-23T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-upgrades-crinetics-on-undervalued-cah-drug-potential 2025-01-23T01:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-upgrades-crinetics-on-undervalued-cah-drug-potential 2025-01-23T01:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/rezafungin-shows-promise-in-treatment-of-severe-candidemia-offering-weekly-dosing-alternative 2025-01-23T01:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezafungin-shows-promise-in-treatment-of-severe-candidemia-offering-weekly-dosing-alternative 2025-01-23T01:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-reports-strong-mrd-business-growth-in-2024-financial-results 2025-01-23T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-reports-strong-mrd-business-growth-in-2024-financial-results 2025-01-23T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/adc-market-surge-clinical-trials-triple-as-next-generation-cancer-therapies-show-promise 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-market-surge-clinical-trials-triple-as-next-generation-cancer-therapies-show-promise 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-multi-omics-study-reveals-promising-drug-combinations-for-acute-myeloid-leukemia-treatment 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-multi-omics-study-reveals-promising-drug-combinations-for-acute-myeloid-leukemia-treatment 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-il-23-inhibitor-qx004n-achieves-100-pasi-response-in-plaque-psoriasis-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-il-23-inhibitor-qx004n-achieves-100-pasi-response-in-plaque-psoriasis-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-tezspire-gains-eu-approval-for-self-administered-pen-injector-in-severe-asthma 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-tezspire-gains-eu-approval-for-self-administered-pen-injector-in-severe-asthma 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-giredestrant-falls-short-in-phase-2-breast-cancer-trial-raising-questions-about-oral-serd-class 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-giredestrant-falls-short-in-phase-2-breast-cancer-trial-raising-questions-about-oral-serd-class 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-imfinzi-bevacizumab-combination-shows-mixed-results-in-early-stage-liver-cancer-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-imfinzi-bevacizumab-combination-shows-mixed-results-in-early-stage-liver-cancer-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iowa-hospital-pioneers-gammatile-brain-cancer-therapy-with-first-state-implementation 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iowa-hospital-pioneers-gammatile-brain-cancer-therapy-with-first-state-implementation 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-engineered-brain-cancer-drug-bpm-31510-iv-enters-phase-1-2-trial-for-glioblastoma 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-engineered-brain-cancer-drug-bpm-31510-iv-enters-phase-1-2-trial-for-glioblastoma 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/spur-therapeutics-to-present-new-clinical-data-on-flt201-gene-therapy-for-gaucher-disease-at-worldsymposium-2025 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spur-therapeutics-to-present-new-clinical-data-on-flt201-gene-therapy-for-gaucher-disease-at-worldsymposium-2025 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-s-abx464-shows-promise-in-reducing-hiv-viral-reservoirs-in-phase-2a-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-s-abx464-shows-promise-in-reducing-hiv-viral-reservoirs-in-phase-2a-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/keytruda-fails-phase-3-trial-in-early-stage-head-and-neck-cancer 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keytruda-fails-phase-3-trial-in-early-stage-head-and-neck-cancer 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trilaciclib-shows-promise-in-protecting-sclc-patients-from-chemotherapy-induced-bone-marrow-damage 2025-01-22T23:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilaciclib-shows-promise-in-protecting-sclc-patients-from-chemotherapy-induced-bone-marrow-damage 2025-01-22T23:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/novel-anti-tigit-therapy-shows-significant-survival-benefit-in-advanced-liver-cancer-trial 2025-01-22T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-anti-tigit-therapy-shows-significant-survival-benefit-in-advanced-liver-cancer-trial 2025-01-22T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-s-zilosul-advances-to-phase-3-trial-for-osteoarthritis-treatment-in-2025 2025-01-22T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-s-zilosul-advances-to-phase-3-trial-for-osteoarthritis-treatment-in-2025 2025-01-22T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-treosulfan-based-regimen-for-pre-transplant-treatment-in-aml-and-mds-patients 2025-01-22T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-treosulfan-based-regimen-for-pre-transplant-treatment-in-aml-and-mds-patients 2025-01-22T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/trialnet-achieves-major-milestone-250000-people-screened-for-type-1-diabetes-risk 2025-01-22T22:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trialnet-achieves-major-milestone-250000-people-screened-for-type-1-diabetes-risk 2025-01-22T22:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-treatment-strategy-shows-promise-for-her2-positive-metastatic-breast-cancer-patients 2025-01-22T22:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-treatment-strategy-shows-promise-for-her2-positive-metastatic-breast-cancer-patients 2025-01-22T22:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-s-bot-bal-combination-shows-promising-results-in-colorectal-cancer-treatment-across-multiple-settings 2025-01-22T19:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-s-bot-bal-combination-shows-promising-results-in-colorectal-cancer-treatment-across-multiple-settings 2025-01-22T19:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-nggt001-shows-promising-safety-profile-in-bietti-s-crystalline-dystrophy-trial 2025-01-22T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-nggt001-shows-promising-safety-profile-in-bietti-s-crystalline-dystrophy-trial 2025-01-22T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/combined-ipl-and-botulinum-toxin-shows-promise-in-treating-rosacea-latin-american-study-finds 2025-01-22T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combined-ipl-and-botulinum-toxin-shows-promise-in-treating-rosacea-latin-american-study-finds 2025-01-22T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/exact-sciences-oncodetect-mrd-test-shows-high-sensitivity-in-post-cancer-monitoring 2025-01-22T19:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exact-sciences-oncodetect-mrd-test-shows-high-sensitivity-in-post-cancer-monitoring 2025-01-22T19:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pet-imaging-probe-revolutionizes-inflammation-detection-and-monitoring 2025-01-22T19:31:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pet-imaging-probe-revolutionizes-inflammation-detection-and-monitoring 2025-01-22T19:31:04+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-s-zanza-shows-promising-results-in-phase-1-cancer-trial-with-atezolizumab-combination 2025-01-22T17:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-s-zanza-shows-promising-results-in-phase-1-cancer-trial-with-atezolizumab-combination 2025-01-22T17:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/ena-respiratory-s-novel-intranasal-antiviral-immune-enhancer-shows-promise-in-phase-ib-trial 2025-01-22T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ena-respiratory-s-novel-intranasal-antiviral-immune-enhancer-shows-promise-in-phase-ib-trial 2025-01-22T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/salubris-reports-promising-phase-2-interim-data-for-novel-heart-failure-drug-jk07 2025-01-22T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salubris-reports-promising-phase-2-interim-data-for-novel-heart-failure-drug-jk07 2025-01-22T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/bio-300-shows-promise-in-improving-lung-function-for-long-covid-patients-in-phase-2-trial 2025-01-22T16:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-300-shows-promise-in-improving-lung-function-for-long-covid-patients-in-phase-2-trial 2025-01-22T16:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/element-29-reports-high-grade-copper-mineralization-in-phase-iii-drilling-at-elida-project 2025-01-22T16:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/element-29-reports-high-grade-copper-mineralization-in-phase-iii-drilling-at-elida-project 2025-01-22T16:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/novel-opioid-like-analgesic-shows-promise-in-phase-3-trial-tris-pharma-reports 2025-01-22T16:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-opioid-like-analgesic-shows-promise-in-phase-3-trial-tris-pharma-reports 2025-01-22T16:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/cosmos-health-acquires-rights-to-novel-anticancer-drug-patents-in-24-6m-deal 2025-01-22T16:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmos-health-acquires-rights-to-novel-anticancer-drug-patents-in-24-6m-deal 2025-01-22T16:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/tenax-therapeutics-strengthens-clinical-leadership-with-appointment-of-gillian-andor-as-vp-of-clinical-operations 2025-01-22T16:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenax-therapeutics-strengthens-clinical-leadership-with-appointment-of-gillian-andor-as-vp-of-clinical-operations 2025-01-22T16:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-appoints-former-ibrutinib-commercial-lead-as-new-cco-ahead-of-pivotal-btk-degrader-trial 2025-01-22T14:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-appoints-former-ibrutinib-commercial-lead-as-new-cco-ahead-of-pivotal-btk-degrader-trial 2025-01-22T14:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-reveals-intensive-blood-pressure-control-reduces-cognitive-decline-risk 2025-01-22T14:01:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-reveals-intensive-blood-pressure-control-reduces-cognitive-decline-risk 2025-01-22T14:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/altamira-therapeutics-partners-with-radiopharmaceutical-company-to-enhance-cancer-treatment-targeting 2025-01-22T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altamira-therapeutics-partners-with-radiopharmaceutical-company-to-enhance-cancer-treatment-targeting 2025-01-22T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cullgen-launches-phase-1-trial-of-novel-non-opioid-pain-treatment-using-protein-degradation-technology 2025-01-22T13:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullgen-launches-phase-1-trial-of-novel-non-opioid-pain-treatment-using-protein-degradation-technology 2025-01-22T13:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-wegovy-shows-enhanced-weight-loss-but-falls-short-of-zepbound-s-efficacy-in-phase-iii-trial 2025-01-22T13:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-wegovy-shows-enhanced-weight-loss-but-falls-short-of-zepbound-s-efficacy-in-phase-iii-trial 2025-01-22T13:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/mgh-mccance-center-launches-pre-ad-initiative-to-prevent-alzheimer-s-disease 2025-01-22T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgh-mccance-center-launches-pre-ad-initiative-to-prevent-alzheimer-s-disease 2025-01-22T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-cro-partnership-drives-successful-phase-i-oncology-trial-for-novel-cancer-therapy 2025-01-22T13:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-cro-partnership-drives-successful-phase-i-oncology-trial-for-novel-cancer-therapy 2025-01-22T13:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/queen-mary-university-launches-ps1-8m-ai-trial-to-transform-emergency-trauma-care 2025-01-22T13:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queen-mary-university-launches-ps1-8m-ai-trial-to-transform-emergency-trauma-care 2025-01-22T13:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/conduit-pharmaceuticals-teams-with-agility-life-sciences-to-advance-autoimmune-drug-formulations 2025-01-22T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conduit-pharmaceuticals-teams-with-agility-life-sciences-to-advance-autoimmune-drug-formulations 2025-01-22T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/gi-innovation-and-lanova-partner-to-develop-novel-combination-therapy-for-pancreatic-cancer 2025-01-22T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-innovation-and-lanova-partner-to-develop-novel-combination-therapy-for-pancreatic-cancer 2025-01-22T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivos-medical-secures-1-9m-nih-grant-to-advance-novel-video-laryngoscope-technology 2025-01-22T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivos-medical-secures-1-9m-nih-grant-to-advance-novel-video-laryngoscope-technology 2025-01-22T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/icelandic-biotech-atx-secures-eur26-5m-to-advance-novel-dementia-treatment 2025-01-22T11:28:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icelandic-biotech-atx-secures-eur26-5m-to-advance-novel-dementia-treatment 2025-01-22T11:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/major-nih-study-targets-opioid-deaths-across-67-communities-in-groundbreaking-trial 2025-01-22T11:28:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-nih-study-targets-opioid-deaths-across-67-communities-in-groundbreaking-trial 2025-01-22T11:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/atn-022-shows-promising-42-9-response-rate-in-advanced-gastric-cancer-trial 2025-01-22T11:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atn-022-shows-promising-42-9-response-rate-in-advanced-gastric-cancer-trial 2025-01-22T11:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/oncoassure-s-novel-prostate-cancer-test-achieves-clinical-validation-us-launch-planned-for-q1-2025 2025-01-22T11:27:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoassure-s-novel-prostate-cancer-test-achieves-clinical-validation-us-launch-planned-for-q1-2025 2025-01-22T11:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/fulcrum-s-oral-scd-therapy-pociredir-advances-in-phase-1b-trial-with-key-data-expected-mid-2024 2025-01-22T11:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulcrum-s-oral-scd-therapy-pociredir-advances-in-phase-1b-trial-with-key-data-expected-mid-2024 2025-01-22T11:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-of-zanza-atezo-combo-shows-early-promise-in-colorectal-cancer-but-questions-remain 2025-01-22T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-of-zanza-atezo-combo-shows-early-promise-in-colorectal-cancer-but-questions-remain 2025-01-22T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-challenges-in-venetoclax-adoption-for-cll-treatment-in-community-settings 2025-01-22T09:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-challenges-in-venetoclax-adoption-for-cll-treatment-in-community-settings 2025-01-22T09:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-repeals-key-drug-pricing-executive-order-creating-uncertainty-in-healthcare-reform 2025-01-22T09:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-repeals-key-drug-pricing-executive-order-creating-uncertainty-in-healthcare-reform 2025-01-22T09:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-s-vt-1953-shows-promise-in-phase-2-trial-for-malignant-fungating-wound-treatment 2025-01-22T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyome-s-vt-1953-shows-promise-in-phase-2-trial-for-malignant-fungating-wound-treatment 2025-01-22T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/patent-reform-could-accelerate-us-biosimilar-market-entry-study-shows 2025-01-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-reform-could-accelerate-us-biosimilar-market-entry-study-shows 2025-01-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-liver-cancer-market-to-reach-11-13-billion-by-2035-driven-by-early-detection-and-novel-therapies 2025-01-22T08:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-liver-cancer-market-to-reach-11-13-billion-by-2035-driven-by-early-detection-and-novel-therapies 2025-01-22T08:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/surgical-treatment-for-sleep-apnea-shows-lower-car-crash-risk-compared-to-cpap-therapy 2025-01-22T08:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgical-treatment-for-sleep-apnea-shows-lower-car-crash-risk-compared-to-cpap-therapy 2025-01-22T08:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-study-of-fostamatinib-for-sickle-cell-disease-treatment 2025-01-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-study-of-fostamatinib-for-sickle-cell-disease-treatment 2025-01-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/emergency-departments-face-critical-need-to-improve-accessibility-for-visually-impaired-patients 2025-01-22T08:00:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emergency-departments-face-critical-need-to-improve-accessibility-for-visually-impaired-patients 2025-01-22T08:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clinical-hold-on-atara-s-cell-therapy-programs-raises-operational-challenges 2025-01-22T06:54:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clinical-hold-on-atara-s-cell-therapy-programs-raises-operational-challenges 2025-01-22T06:54:29+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-expands-portfolio-with-novel-adc-for-gi-cancers-reports-strong-nsclc-trial-results 2025-01-22T06:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-biopharma-expands-portfolio-with-novel-adc-for-gi-cancers-reports-strong-nsclc-trial-results 2025-01-22T06:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-ps150m-ai-initiative-to-transform-nhs-healthcare-delivery 2025-01-22T06:04:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-ps150m-ai-initiative-to-transform-nhs-healthcare-delivery 2025-01-22T06:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pipeline-therapies-show-promise-for-pulmonary-sarcoidosis-treatment 2025-01-22T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pipeline-therapies-show-promise-for-pulmonary-sarcoidosis-treatment 2025-01-22T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/tuxedo-trial-success-combined-therapy-approach-shows-promise-in-invasive-bladder-cancer-treatment 2025-01-22T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuxedo-trial-success-combined-therapy-approach-shows-promise-in-invasive-bladder-cancer-treatment 2025-01-22T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/xilio-therapeutics-reports-promising-phase-2-data-for-vilastobart-in-combination-with-atezolizumab-for-metastatic-mss-crc 2025-01-22T04:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xilio-therapeutics-reports-promising-phase-2-data-for-vilastobart-in-combination-with-atezolizumab-for-metastatic-mss-crc 2025-01-22T04:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/natera-to-unveil-groundbreaking-data-at-2025-asco-gi-symposium 2025-01-22T04:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-to-unveil-groundbreaking-data-at-2025-asco-gi-symposium 2025-01-22T04:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/budget-2025-advances-green-energy-corridor-to-phase-iii 2025-01-22T04:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/budget-2025-advances-green-energy-corridor-to-phase-iii 2025-01-22T04:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-fighting-drug-sparks-hiv-treatment-breakthrough 2025-01-22T04:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-fighting-drug-sparks-hiv-treatment-breakthrough 2025-01-22T04:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-accepts-new-drug-application-for-covid-19-treatment-ensitrelvir 2025-01-22T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-accepts-new-drug-application-for-covid-19-treatment-ensitrelvir 2025-01-22T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-weight-loss-pill-orforglipron-aims-for-fda-approval-by-2026 2025-01-22T04:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-weight-loss-pill-orforglipron-aims-for-fda-approval-by-2026 2025-01-22T04:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-s-potential-hhs-leadership-raises-concerns-over-vaccine-programs-and-nih-research-future 2025-01-22T04:13:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-s-potential-hhs-leadership-raises-concerns-over-vaccine-programs-and-nih-research-future 2025-01-22T04:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-haduvio-shows-promise-for-ipf-related-cough-treatment-receives-buy-rating 2025-01-22T03:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trevi-therapeutics-haduvio-shows-promise-for-ipf-related-cough-treatment-receives-buy-rating 2025-01-22T03:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-completes-patient-enrolment-for-phase-ii-cancer-trial 2025-01-22T01:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-completes-patient-enrolment-for-phase-ii-cancer-trial 2025-01-22T01:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/everolimus-combined-with-lanreotide-shows-promise-in-extending-pfs-for-advanced-gep-nets 2025-01-22T01:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everolimus-combined-with-lanreotide-shows-promise-in-extending-pfs-for-advanced-gep-nets 2025-01-22T01:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-oral-pcsk9-inhibitor-shows-promising-52-ldl-reduction-in-phase-1-trial 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-oral-pcsk9-inhibitor-shows-promising-52-ldl-reduction-in-phase-1-trial 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-drug-candidate-erso-tfpy-eliminates-breast-cancer-tumors-in-mice 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-drug-candidate-erso-tfpy-eliminates-breast-cancer-tumors-in-mice 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-long-term-effectiveness-of-dolutegravir-lamivudine-hiv-treatment-in-real-world-settings 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-long-term-effectiveness-of-dolutegravir-lamivudine-hiv-treatment-in-real-world-settings 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-trulicity-label-to-include-cardiovascular-risk-reduction-in-type-2-diabetes 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-trulicity-label-to-include-cardiovascular-risk-reduction-in-type-2-diabetes 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/island-pharmaceuticals-completes-phase-2b-dosing-for-isla-101-dengue-fever-treatment 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/island-pharmaceuticals-completes-phase-2b-dosing-for-isla-101-dengue-fever-treatment 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-first-to-approve-amgen-s-novel-osteoporosis-drug-evenity-amid-safety-scrutiny 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-first-to-approve-amgen-s-novel-osteoporosis-drug-evenity-amid-safety-scrutiny 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-jardiance-approval-for-all-heart-failure-patients-regardless-of-ejection-fraction 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-jardiance-approval-for-all-heart-failure-patients-regardless-of-ejection-fraction 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-launches-groundbreaking-human-challenge-study-for-relapsing-malaria-research 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-launches-groundbreaking-human-challenge-study-for-relapsing-malaria-research 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/salignostics-saliva-based-hiv-test-shows-90-accuracy-in-ethiopian-clinical-trial 2025-01-21T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salignostics-saliva-based-hiv-test-shows-90-accuracy-in-ethiopian-clinical-trial 2025-01-21T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-resumes-uniqure-s-phase-3-gene-therapy-trial-for-haemophilia-b-after-cancer-case-review 2025-01-21T23:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-resumes-uniqure-s-phase-3-gene-therapy-trial-for-haemophilia-b-after-cancer-case-review 2025-01-21T23:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-to-unveil-updated-aspen-06-phase-2-trial-data-at-virtual-event 2025-01-21T23:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-to-unveil-updated-aspen-06-phase-2-trial-data-at-virtual-event 2025-01-21T23:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/kalvista-advances-hae-treatment-with-sebetralstat-s-orphan-drug-designation-and-nda-submission-in-japan 2025-01-21T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalvista-advances-hae-treatment-with-sebetralstat-s-orphan-drug-designation-and-nda-submission-in-japan 2025-01-21T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-covid-19-does-not-worsen-multiple-sclerosis-symptoms 2025-01-21T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-covid-19-does-not-worsen-multiple-sclerosis-symptoms 2025-01-21T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/key-clinical-trial-updates-to-watch-at-asco-gi-2025 2025-01-21T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/key-clinical-trial-updates-to-watch-at-asco-gi-2025 2025-01-21T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/belhaven-biopharma-secures-11m-to-propel-nasdepi-r-a-nasal-dry-powder-breakthrough-for-anaphylaxis-treatment 2025-01-21T22:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belhaven-biopharma-secures-11m-to-propel-nasdepi-r-a-nasal-dry-powder-breakthrough-for-anaphylaxis-treatment 2025-01-21T22:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-hiv-vaccine-candidate-activates-key-immune-cells 2025-01-21T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-hiv-vaccine-candidate-activates-key-immune-cells 2025-01-21T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medibeacon-s-innovative-kidney-function-monitoring-system 2025-01-21T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medibeacon-s-innovative-kidney-function-monitoring-system 2025-01-21T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/cytonics-completes-phase-1-trial-for-osteoarthritis-therapy-cyt-108-with-promising-safety-profile 2025-01-21T22:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytonics-completes-phase-1-trial-for-osteoarthritis-therapy-cyt-108-with-promising-safety-profile 2025-01-21T22:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/adagene-to-present-adg126-keytruda-combination-data-for-mss-colorectal-cancer-at-asco-gi-2025 2025-01-21T22:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adagene-to-present-adg126-keytruda-combination-data-for-mss-colorectal-cancer-at-asco-gi-2025 2025-01-21T22:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-s-ozekibart-shows-promise-in-phase-1-colorectal-cancer-trial 2025-01-21T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-s-ozekibart-shows-promise-in-phase-1-colorectal-cancer-trial 2025-01-21T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sonnet-biotherapeutics-advances-son-1010-combination-trial-for-sarcoma-treatment 2025-01-21T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonnet-biotherapeutics-advances-son-1010-combination-trial-for-sarcoma-treatment 2025-01-21T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-ck-586-advances-in-phase-2-amber-hfpef-trial-bolstering-buy-ratings 2025-01-21T20:01:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-ck-586-advances-in-phase-2-amber-hfpef-trial-bolstering-buy-ratings 2025-01-21T20:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-s-neurorestore-acd856-gains-recognition-at-alzheimer-s-congress-ad-pd-2025 2025-01-21T19:35:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzecure-s-neurorestore-acd856-gains-recognition-at-alzheimer-s-congress-ad-pd-2025 2025-01-21T19:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-gene-therapy-and-management-strategies-for-chronic-diseases-highlighted-in-recent-studies 2025-01-21T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-gene-therapy-and-management-strategies-for-chronic-diseases-highlighted-in-recent-studies 2025-01-21T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-infertility-treatment-rhfsh-ctp-shows-promise-in-clinical-trials 2025-01-21T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-infertility-treatment-rhfsh-ctp-shows-promise-in-clinical-trials 2025-01-21T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/stuart-therapeutics-completes-phase-3-clinical-trial-for-dry-eye-disease-treatment 2025-01-21T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stuart-therapeutics-completes-phase-3-clinical-trial-for-dry-eye-disease-treatment 2025-01-21T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/osimertinib-pill-doubles-survival-time-for-lung-cancer-patients-now-available-on-nhs 2025-01-21T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osimertinib-pill-doubles-survival-time-for-lung-cancer-patients-now-available-on-nhs 2025-01-21T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-18f-florbetaben-for-cardiac-amyloidosis-diagnosis 2025-01-21T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-18f-florbetaben-for-cardiac-amyloidosis-diagnosis 2025-01-21T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-obe-cel-for-adult-r-r-all-marking-a-significant-advance-in-car-t-cell-therapy 2025-01-21T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-obe-cel-for-adult-r-r-all-marking-a-significant-advance-in-car-t-cell-therapy 2025-01-21T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-jenavalve-trilogy-system-for-expanded-indications-in-aortic-regurgitation 2025-01-21T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-jenavalve-trilogy-system-for-expanded-indications-in-aortic-regurgitation 2025-01-21T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-swedish-match-s-zyn-nicotine-pouches-as-a-safer-alternative-to-smoking 2025-01-21T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-swedish-match-s-zyn-nicotine-pouches-as-a-safer-alternative-to-smoking 2025-01-21T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-inflammatix-s-triverity-test-for-rapid-infection-diagnosis 2025-01-21T19:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-inflammatix-s-triverity-test-for-rapid-infection-diagnosis 2025-01-21T19:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/actg-launches-second-hiv-cure-clinical-trial-in-africa 2025-01-21T19:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actg-launches-second-hiv-cure-clinical-trial-in-africa 2025-01-21T19:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/new-insights-on-diet-and-exercise-impacting-prostate-cancer-outcomes-revealed-at-pcf-scientific-retreat 2025-01-21T19:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-insights-on-diet-and-exercise-impacting-prostate-cancer-outcomes-revealed-at-pcf-scientific-retreat 2025-01-21T19:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/prim-er-trial-finds-palliative-care-training-in-emergency-departments-does-not-reduce-hospital-admissions 2025-01-21T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prim-er-trial-finds-palliative-care-training-in-emergency-departments-does-not-reduce-hospital-admissions 2025-01-21T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-phase-ii-iii-platform-trial-design-for-lassa-fever-therapeutics-announced 2025-01-21T19:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-phase-ii-iii-platform-trial-design-for-lassa-fever-therapeutics-announced 2025-01-21T19:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/lipidor-reaches-milestone-with-half-of-patients-enrolled-in-phase-iii-psoriasis-study 2025-01-21T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipidor-reaches-milestone-with-half-of-patients-enrolled-in-phase-iii-psoriasis-study 2025-01-21T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-s-maat033-shows-promising-safety-profile-in-phase-2b-clinical-trial 2025-01-21T19:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-s-maat033-shows-promising-safety-profile-in-phase-2b-clinical-trial 2025-01-21T19:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-reports-positive-second-dsmb-review-for-phase-2b-clinical-trial-of-maat033 2025-01-21T19:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-reports-positive-second-dsmb-review-for-phase-2b-clinical-trial-of-maat033 2025-01-21T19:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/kairos-pharma-advances-oncology-therapeutics-with-env105-in-clinical-trials 2025-01-21T17:01:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kairos-pharma-advances-oncology-therapeutics-with-env105-in-clinical-trials 2025-01-21T17:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/neogap-therapeutics-advances-personalized-cancer-immunotherapy-into-clinical-trials 2025-01-21T17:01:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neogap-therapeutics-advances-personalized-cancer-immunotherapy-into-clinical-trials 2025-01-21T17:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/sionna-and-odyssey-therapeutics-announce-plans-for-ipos-amidst-biotech-funding-trends 2025-01-21T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sionna-and-odyssey-therapeutics-announce-plans-for-ipos-amidst-biotech-funding-trends 2025-01-21T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-advances-onp-002-phase-ii-trials-and-appoints-new-interim-ceo 2025-01-21T16:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-advances-onp-002-phase-ii-trials-and-appoints-new-interim-ceo 2025-01-21T16:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/kn026-and-docetaxel-combination-shows-promising-results-in-her2-metastatic-breast-cancer-treatment 2025-01-21T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kn026-and-docetaxel-combination-shows-promising-results-in-her2-metastatic-breast-cancer-treatment 2025-01-21T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/anlotinib-combined-with-egfr-tkis-shows-promise-in-extending-progression-free-survival-in-advanced-nsclc 2025-01-21T16:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anlotinib-combined-with-egfr-tkis-shows-promise-in-extending-progression-free-survival-in-advanced-nsclc 2025-01-21T16:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/exploring-treatment-patterns-in-atrial-fibrillation-insights-from-the-gloria-af-registry 2025-01-21T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exploring-treatment-patterns-in-atrial-fibrillation-insights-from-the-gloria-af-registry 2025-01-21T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/amplify-trial-reveals-promising-new-treatment-paradigm-for-treatment-naive-chronic-lymphocytic-leukemia 2025-01-21T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplify-trial-reveals-promising-new-treatment-paradigm-for-treatment-naive-chronic-lymphocytic-leukemia 2025-01-21T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-revolutionizes-cancer-diagnosis-and-long-acting-hiv-prevention-shows-promise 2025-01-21T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-revolutionizes-cancer-diagnosis-and-long-acting-hiv-prevention-shows-promise 2025-01-21T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/intelligenome-s-crispr-tb-blood-test-receives-fda-breakthrough-device-designation 2025-01-21T16:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligenome-s-crispr-tb-blood-test-receives-fda-breakthrough-device-designation 2025-01-21T16:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-initiates-phase-2b-trial-for-halneuron-r-in-chemotherapy-induced-neuropathic-pain 2025-01-21T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogwood-therapeutics-initiates-phase-2b-trial-for-halneuron-r-in-chemotherapy-induced-neuropathic-pain 2025-01-21T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-esketamine-as-first-monotherapy-for-treatment-resistant-depression 2025-01-21T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-esketamine-as-first-monotherapy-for-treatment-resistant-depression 2025-01-21T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-spravato-as-first-standalone-treatment-for-major-depressive-disorder 2025-01-21T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-spravato-as-first-standalone-treatment-for-major-depressive-disorder 2025-01-21T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-initiates-prime-phase-1b-clinical-study-for-gemini-in-ckd-patients 2025-01-21T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revelation-biosciences-initiates-prime-phase-1b-clinical-study-for-gemini-in-ckd-patients 2025-01-21T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-to-present-clinical-data-on-tyvaso-dpi-at-pvri-2025-annual-congress 2025-01-21T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-to-present-clinical-data-on-tyvaso-dpi-at-pvri-2025-annual-congress 2025-01-21T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/century-therapeutics-advances-autoimmune-disease-treatment-with-phase-1-2-trial-of-ipsc-derived-cnty-101 2025-01-21T16:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-therapeutics-advances-autoimmune-disease-treatment-with-phase-1-2-trial-of-ipsc-derived-cnty-101 2025-01-21T16:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/shuttle-pharma-achieves-25-enrollment-in-phase-2-trial-for-glioblastoma-treatment 2025-01-21T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shuttle-pharma-achieves-25-enrollment-in-phase-2-trial-for-glioblastoma-treatment 2025-01-21T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/filament-health-s-botanical-psilocybin-to-undergo-clinical-trials-at-uw-madison 2025-01-21T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/filament-health-s-botanical-psilocybin-to-undergo-clinical-trials-at-uw-madison 2025-01-21T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-amx0114-phase-1-trial-for-als-treatment 2025-01-21T16:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-amx0114-phase-1-trial-for-als-treatment 2025-01-21T16:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/helius-medical-technologies-exceeds-enrollment-goals-for-stroke-trial-of-pons-device 2025-01-21T16:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helius-medical-technologies-exceeds-enrollment-goals-for-stroke-trial-of-pons-device 2025-01-21T16:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/kiromic-biopharma-reports-promising-tumor-reduction-in-deltacel-01-phase-1-trial-for-nsclc 2025-01-21T16:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiromic-biopharma-reports-promising-tumor-reduction-in-deltacel-01-phase-1-trial-for-nsclc 2025-01-21T16:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-and-abbvie-partner-on-novel-anti-inflammatory-program-in-713m-deal 2025-01-21T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-and-abbvie-partner-on-novel-anti-inflammatory-program-in-713m-deal 2025-01-21T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-therapeutics-names-dr-naji-gehchan-as-new-chief-medical-officer-to-advance-autoimmune-cell-therapy-programs 2025-01-21T16:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyverna-therapeutics-names-dr-naji-gehchan-as-new-chief-medical-officer-to-advance-autoimmune-cell-therapy-programs 2025-01-21T16:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/astorg-acquires-fujifilm-irvine-scientific-s-medical-media-business-unit-to-expand-reproductive-health-portfolio 2025-01-21T15:25:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astorg-acquires-fujifilm-irvine-scientific-s-medical-media-business-unit-to-expand-reproductive-health-portfolio 2025-01-21T15:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-bluejay-therapeutics-brelovitug-for-chronic-hepatitis-delta-treatment 2025-01-21T15:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-bluejay-therapeutics-brelovitug-for-chronic-hepatitis-delta-treatment 2025-01-21T15:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/nacuity-pharmaceuticals-npi-001-receives-fda-fast-track-designation-for-retinitis-pigmentosa-treatment 2025-01-21T14:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nacuity-pharmaceuticals-npi-001-receives-fda-fast-track-designation-for-retinitis-pigmentosa-treatment 2025-01-21T14:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-initiates-phase-2-clinical-trial-for-ck-586-in-hfpef-patients 2025-01-21T13:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-initiates-phase-2-clinical-trial-for-ck-586-in-hfpef-patients 2025-01-21T13:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/ascletis-reports-promising-phase-ia-results-for-oral-glp-1r-agonist-asc30-in-obesity-treatment 2025-01-21T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascletis-reports-promising-phase-ia-results-for-oral-glp-1r-agonist-asc30-in-obesity-treatment 2025-01-21T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-plc-s-hlab-secures-ps2-7-million-contract-for-influenza-drug-phase-2-study 2025-01-21T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hvivo-plc-s-hlab-secures-ps2-7-million-contract-for-influenza-drug-phase-2-study 2025-01-21T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/aravax-advances-in-food-allergy-treatment-with-new-leadership-and-phase-2-trial-progress 2025-01-21T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aravax-advances-in-food-allergy-treatment-with-new-leadership-and-phase-2-trial-progress 2025-01-21T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-and-nippon-shinyaku-partner-to-advance-gene-therapies-for-rare-diseases 2025-01-21T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-and-nippon-shinyaku-partner-to-advance-gene-therapies-for-rare-diseases 2025-01-21T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-grants-precision-medicine-patent-to-diamyd-medical-for-autoimmune-diabetes-treatment 2025-01-21T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-grants-precision-medicine-patent-to-diamyd-medical-for-autoimmune-diabetes-treatment 2025-01-21T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/scilex-holding-company-submits-fda-application-for-elyxyb-r-in-acute-pain-treatment 2025-01-21T13:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scilex-holding-company-submits-fda-application-for-elyxyb-r-in-acute-pain-treatment 2025-01-21T13:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-drugs-to-enter-clinical-trials-this-year-says-deepmind-ceo 2025-01-21T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-drugs-to-enter-clinical-trials-this-year-says-deepmind-ceo 2025-01-21T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/nvidia-and-innophore-launch-ai-powered-cavitomix-platform-for-drug-safety-screening 2025-01-21T13:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nvidia-and-innophore-launch-ai-powered-cavitomix-platform-for-drug-safety-screening 2025-01-21T13:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-secures-590m-hhs-award-to-advance-mrna-based-pandemic-flu-vaccines 2025-01-21T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-secures-590m-hhs-award-to-advance-mrna-based-pandemic-flu-vaccines 2025-01-21T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-expands-global-reach-with-firdapse-launch-in-japan-and-agamree-review-in-canada 2025-01-21T12:00:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-pharmaceuticals-expands-global-reach-with-firdapse-launch-in-japan-and-agamree-review-in-canada 2025-01-21T12:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/yale-researchers-pioneer-quantitative-ihc-testing-to-improve-breast-cancer-diagnostic-accuracy 2025-01-21T12:00:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-researchers-pioneer-quantitative-ihc-testing-to-improve-breast-cancer-diagnostic-accuracy 2025-01-21T12:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/advarra-integrates-eirb-with-study-collaboration-platform-to-streamline-clinical-trial-startup 2025-01-21T11:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advarra-integrates-eirb-with-study-collaboration-platform-to-streamline-clinical-trial-startup 2025-01-21T11:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/taho-pharmaceuticals-completes-pivotal-trial-for-first-oral-dissolving-film-anticoagulant 2025-01-21T11:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taho-pharmaceuticals-completes-pivotal-trial-for-first-oral-dissolving-film-anticoagulant 2025-01-21T11:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-takes-center-stage-at-sogo-2025-new-frontiers-in-gi-cancer-treatment 2025-01-21T11:00:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-takes-center-stage-at-sogo-2025-new-frontiers-in-gi-cancer-treatment 2025-01-21T11:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/bioversys-announces-ipo-to-fund-phase-3-trials-for-bv100-and-alpibectir 2025-01-21T10:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioversys-announces-ipo-to-fund-phase-3-trials-for-bv100-and-alpibectir 2025-01-21T10:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-2-study-of-nbtxr3-for-unresectable-non-small-cell-lung-cancer 2025-01-21T10:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-2-study-of-nbtxr3-for-unresectable-non-small-cell-lung-cancer 2025-01-21T10:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-and-askhelpu-collaborate-on-groundbreaking-als-treatment-development 2025-01-21T10:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-and-askhelpu-collaborate-on-groundbreaking-als-treatment-development 2025-01-21T10:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-cialis-over-the-counter-study-marking-a-milestone-for-opella 2025-01-21T10:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-cialis-over-the-counter-study-marking-a-milestone-for-opella 2025-01-21T10:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/new-ps7m-clinical-trial-unit-in-birmingham-aims-to-transform-health-outcomes-in-deprived-areas 2025-01-21T10:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ps7m-clinical-trial-unit-in-birmingham-aims-to-transform-health-outcomes-in-deprived-areas 2025-01-21T10:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/rs-biotherapeutics-novel-compound-shows-promising-anti-inflammatory-effects-in-human-lung-tissue-study 2025-01-21T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rs-biotherapeutics-novel-compound-shows-promising-anti-inflammatory-effects-in-human-lung-tissue-study 2025-01-21T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-education-reform-early-intervention-crucial-for-combating-provider-burnout-crisis 2025-01-21T08:36:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-education-reform-early-intervention-crucial-for-combating-provider-burnout-crisis 2025-01-21T08:36:57+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-to-host-expert-panel-on-lx9211-novel-non-opioid-treatment-for-diabetic-neuropathic-pain 2025-01-21T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-to-host-expert-panel-on-lx9211-novel-non-opioid-treatment-for-diabetic-neuropathic-pain 2025-01-21T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-revolutionizes-cancer-treatment-ai-and-precision-medicine-shape-future-of-oncology 2025-01-21T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-profiling-revolutionizes-cancer-treatment-ai-and-precision-medicine-shape-future-of-oncology 2025-01-21T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-neural-interface-technology-enables-paralyzed-man-to-control-virtual-drone-with-his-mind 2025-01-21T07:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-neural-interface-technology-enables-paralyzed-man-to-control-virtual-drone-with-his-mind 2025-01-21T07:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharmaceuticals-launches-phytonadione-injectable-emulsion-for-blood-clotting-issues 2025-01-21T07:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-pharmaceuticals-launches-phytonadione-injectable-emulsion-for-blood-clotting-issues 2025-01-21T07:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-approaches-in-clinical-trials-lessons-from-recovery-and-taste 2025-01-21T07:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-approaches-in-clinical-trials-lessons-from-recovery-and-taste 2025-01-21T07:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/yoltech-therapeutics-launches-clinical-trial-for-yolt-204-a-novel-gene-editing-therapy-for-b-thalassemia 2025-01-21T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yoltech-therapeutics-launches-clinical-trial-for-yolt-204-a-novel-gene-editing-therapy-for-b-thalassemia 2025-01-21T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/swedish-study-reveals-5-fold-higher-infection-risk-in-multiple-myeloma-patients 2025-01-21T07:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swedish-study-reveals-5-fold-higher-infection-risk-in-multiple-myeloma-patients 2025-01-21T07:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-transformation-in-biopharma-data-quality-and-regulatory-compliance-key-to-2025-success 2025-01-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-transformation-in-biopharma-data-quality-and-regulatory-compliance-key-to-2025-success 2025-01-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-review-designations-hit-record-high-during-pandemic-reflecting-40-years-of-drug-development-evolution 2025-01-21T03:12:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-review-designations-hit-record-high-during-pandemic-reflecting-40-years-of-drug-development-evolution 2025-01-21T03:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-unveils-new-international-reliance-framework-for-faster-medical-product-approvals 2025-01-21T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-unveils-new-international-reliance-framework-for-faster-medical-product-approvals 2025-01-21T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-completes-patient-dosing-in-phase-ii-trial-for-topical-gel-targeting-skin-infections 2025-01-21T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recce-pharmaceuticals-completes-patient-dosing-in-phase-ii-trial-for-topical-gel-targeting-skin-infections 2025-01-21T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/awakn-life-sciences-receives-fda-support-for-esketamine-based-treatment-for-alcohol-use-disorder 2025-01-21T01:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/awakn-life-sciences-receives-fda-support-for-esketamine-based-treatment-for-alcohol-use-disorder 2025-01-21T01:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-advances-firefly-2-trial-and-reports-progress-in-day301-study 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-biopharmaceuticals-advances-firefly-2-trial-and-reports-progress-in-day301-study 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-gives-positive-pre-ind-feedback-for-novel-mrna-therapy-targeting-familial-hypercholesterolemia 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-gives-positive-pre-ind-feedback-for-novel-mrna-therapy-targeting-familial-hypercholesterolemia 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/catalent-and-galapagos-partner-to-advance-decentralized-car-t-manufacturing-for-nhl-treatment 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalent-and-galapagos-partner-to-advance-decentralized-car-t-manufacturing-for-nhl-treatment 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advance-trial-analysis-intensive-glucose-control-benefits-type-2-diabetes-patients-regardless-of-disease-onset-age 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advance-trial-analysis-intensive-glucose-control-benefits-type-2-diabetes-patients-regardless-of-disease-onset-age 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiovascular-risks-of-tisagenlecleucel-in-pediatric-patients-new-faers-analysis-reveals-critical-safety-signals 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiovascular-risks-of-tisagenlecleucel-in-pediatric-patients-new-faers-analysis-reveals-critical-safety-signals 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/weekly-chemotherapy-regimen-shows-promise-in-early-stage-breast-cancer-treatment 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weekly-chemotherapy-regimen-shows-promise-in-early-stage-breast-cancer-treatment 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-explores-fdg-pet-ct-guided-adaptive-radiotherapy-in-stage-iii-non-small-cell-lung-cancer 2025-01-20T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-explores-fdg-pet-ct-guided-adaptive-radiotherapy-in-stage-iii-non-small-cell-lung-cancer 2025-01-20T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/nutraceutical-supplement-shows-promise-in-treating-male-hair-thinning 2025-01-20T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutraceutical-supplement-shows-promise-in-treating-male-hair-thinning 2025-01-20T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-auriga-trial-explores-daratumumab-and-lenalidomide-in-newly-diagnosed-multiple-myeloma 2025-01-20T22:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-auriga-trial-explores-daratumumab-and-lenalidomide-in-newly-diagnosed-multiple-myeloma 2025-01-20T22:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-malaria-vaccine-research-validation-of-a-multiplexed-immunoassay-for-r21-mm-vaccine 2025-01-20T22:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-malaria-vaccine-research-validation-of-a-multiplexed-immunoassay-for-r21-mm-vaccine 2025-01-20T22:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-advances-dmd-gene-therapy-with-sgt-003-in-inspire-duchenne-trial 2025-01-20T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-advances-dmd-gene-therapy-with-sgt-003-in-inspire-duchenne-trial 2025-01-20T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/6-2-million-grant-advances-mrna-vaccine-research-for-rift-valley-fever 2025-01-20T22:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/6-2-million-grant-advances-mrna-vaccine-research-for-rift-valley-fever 2025-01-20T22:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/largest-study-on-glp-1-drugs-reveals-broad-health-benefits-beyond-diabetes-and-weight-loss 2025-01-20T20:01:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/largest-study-on-glp-1-drugs-reveals-broad-health-benefits-beyond-diabetes-and-weight-loss 2025-01-20T20:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/cascada-silver-corp-adjusts-payment-terms-for-angie-project-to-focus-on-exploration 2025-01-20T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cascada-silver-corp-adjusts-payment-terms-for-angie-project-to-focus-on-exploration 2025-01-20T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-circulating-tumor-dna-analysis-for-early-stage-and-locally-advanced-nsclc 2025-01-20T19:33:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-circulating-tumor-dna-analysis-for-early-stage-and-locally-advanced-nsclc 2025-01-20T19:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-cancer-therapy-modified-virus-shows-promise-in-shrinking-tumors 2025-01-20T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-cancer-therapy-modified-virus-shows-promise-in-shrinking-tumors 2025-01-20T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-takeda-s-fruzaqlatm-for-metastatic-colorectal-cancer-treatment 2025-01-20T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-takeda-s-fruzaqlatm-for-metastatic-colorectal-cancer-treatment 2025-01-20T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-vabysmo-r-pre-filled-syringe-for-treating-leading-causes-of-vision-loss 2025-01-20T19:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-vabysmo-r-pre-filled-syringe-for-treating-leading-causes-of-vision-loss 2025-01-20T19:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/lava-therapeutics-halts-development-of-lava-1207-for-mcrpc 2025-01-20T19:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lava-therapeutics-halts-development-of-lava-1207-for-mcrpc 2025-01-20T19:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/beta-blockers-offer-new-hope-for-huntington-s-disease-patients 2025-01-20T19:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-blockers-offer-new-hope-for-huntington-s-disease-patients 2025-01-20T19:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-efficacy-of-rapid-ring-vaccination-strategy-in-ebola-outbreak-response 2025-01-20T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-efficacy-of-rapid-ring-vaccination-strategy-in-ebola-outbreak-response 2025-01-20T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-s-chikungunya-vaccine-shows-high-sustained-immune-response-in-adolescents 2025-01-20T19:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-s-chikungunya-vaccine-shows-high-sustained-immune-response-in-adolescents 2025-01-20T19:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/fedratinib-demonstrates-efficacy-in-treating-chronic-neutrophilic-leukemia-and-mds-mpn 2025-01-20T19:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fedratinib-demonstrates-efficacy-in-treating-chronic-neutrophilic-leukemia-and-mds-mpn 2025-01-20T19:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/odyssey-therapeutics-files-for-u-s-ipo-advances-clinical-trials-for-autoimmune-diseases 2025-01-20T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odyssey-therapeutics-files-for-u-s-ipo-advances-clinical-trials-for-autoimmune-diseases 2025-01-20T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/ebr-systems-awaits-fda-approval-for-novel-wireless-pacemaker-lead 2025-01-20T16:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebr-systems-awaits-fda-approval-for-novel-wireless-pacemaker-lead 2025-01-20T16:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/handok-s-vyvgart-receives-approval-for-generalized-myasthenia-gravis-treatment-in-south-korea 2025-01-20T16:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/handok-s-vyvgart-receives-approval-for-generalized-myasthenia-gravis-treatment-in-south-korea 2025-01-20T16:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-gilead-s-livdelzi-for-treating-primary-biliary-cholangitis-in-adults 2025-01-20T16:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-gilead-s-livdelzi-for-treating-primary-biliary-cholangitis-in-adults 2025-01-20T16:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/intensive-blood-pressure-targets-show-promise-for-ckd-patients-in-clinical-practice 2025-01-20T16:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensive-blood-pressure-targets-show-promise-for-ckd-patients-in-clinical-practice 2025-01-20T16:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-collaborates-with-israeli-mental-health-center-for-innovative-ptsd-mdma-trial 2025-01-20T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmala-collaborates-with-israeli-mental-health-center-for-innovative-ptsd-mdma-trial 2025-01-20T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-evaluates-efficacy-of-quadruple-single-pill-combination-for-resistant-hypertension 2025-01-20T16:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-evaluates-efficacy-of-quadruple-single-pill-combination-for-resistant-hypertension 2025-01-20T16:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-ps6-5m-brain-computer-interface-trial-for-mood-enhancement-treatment 2025-01-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-launches-ps6-5m-brain-computer-interface-trial-for-mood-enhancement-treatment 2025-01-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-panel-debates-treatment-strategies-for-high-risk-relapsed-cll-patient-with-cardiac-complications 2025-01-20T14:30:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-panel-debates-treatment-strategies-for-high-risk-relapsed-cll-patient-with-cardiac-complications 2025-01-20T14:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-01-20T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-01-20T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-biosciences-announces-rights-issue-to-fund-mitazalimab-development 2025-01-20T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-biosciences-announces-rights-issue-to-fund-mitazalimab-development 2025-01-20T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/gesynta-pharma-secures-29m-for-phase-ii-trial-of-non-hormonal-endometriosis-treatment 2025-01-20T13:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gesynta-pharma-secures-29m-for-phase-ii-trial-of-non-hormonal-endometriosis-treatment 2025-01-20T13:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-sulforaphane-shows-promise-in-reducing-negative-symptoms-of-schizophrenia 2025-01-20T13:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-sulforaphane-shows-promise-in-reducing-negative-symptoms-of-schizophrenia 2025-01-20T13:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-study-aims-to-standardize-return-of-individual-research-results-in-lung-health-cohort 2025-01-20T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-study-aims-to-standardize-return-of-individual-research-results-in-lung-health-cohort 2025-01-20T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/feinstein-institutes-awarded-2-9m-nih-grant-to-study-ghrelin-s-role-in-combating-radiation-induced-gi-syndrome 2025-01-20T13:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/feinstein-institutes-awarded-2-9m-nih-grant-to-study-ghrelin-s-role-in-combating-radiation-induced-gi-syndrome 2025-01-20T13:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-witnesses-70-surge-in-phase-i-advanced-therapy-clinical-trials-in-2024 2025-01-20T13:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-witnesses-70-surge-in-phase-i-advanced-therapy-clinical-trials-in-2024 2025-01-20T13:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-for-ocular-hypertension-treatment-expands-with-70-drug-candidates-under-development 2025-01-20T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-for-ocular-hypertension-treatment-expands-with-70-drug-candidates-under-development 2025-01-20T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/merus-n-v-advances-in-oncology-with-bizengri-approval-and-promising-phase-2-data-for-petosemtamab 2025-01-20T11:30:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merus-n-v-advances-in-oncology-with-bizengri-approval-and-promising-phase-2-data-for-petosemtamab 2025-01-20T11:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-and-keymed-strike-520m-licensing-deal-with-prolium-for-novel-cd20xcd3-bispecific-antibody 2025-01-20T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-and-keymed-strike-520m-licensing-deal-with-prolium-for-novel-cd20xcd3-bispecific-antibody 2025-01-20T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-combined-with-chemotherapy-shows-promise-but-faces-cost-effectiveness-challenges-in-treating-advanced-endometrial-cancer 2025-01-20T10:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-combined-with-chemotherapy-shows-promise-but-faces-cost-effectiveness-challenges-in-treating-advanced-endometrial-cancer 2025-01-20T10:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-expanded-use-of-jemperli-plus-chemotherapy-for-endometrial-cancer 2025-01-20T10:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-expanded-use-of-jemperli-plus-chemotherapy-for-endometrial-cancer 2025-01-20T10:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/systematic-review-questions-impact-of-genomic-classifier-tests-in-prostate-cancer-treatment-decisions 2025-01-20T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systematic-review-questions-impact-of-genomic-classifier-tests-in-prostate-cancer-treatment-decisions 2025-01-20T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tofacitinib-shows-promising-results-in-phase-iii-trial-for-ankylosing-spondylitis-treatment 2025-01-20T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tofacitinib-shows-promising-results-in-phase-iii-trial-for-ankylosing-spondylitis-treatment 2025-01-20T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneel-therapeutics-introduces-affordable-car-t-cell-therapy-for-non-hodgkin-s-lymphoma-in-india 2025-01-20T08:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneel-therapeutics-introduces-affordable-car-t-cell-therapy-for-non-hodgkin-s-lymphoma-in-india 2025-01-20T08:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-in-atrial-fibrillation-trial 2025-01-20T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-farapulse-pfa-system-shows-promising-results-in-atrial-fibrillation-trial 2025-01-20T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-research-reveals-critical-role-of-mucus-plugging-in-severe-and-fatal-asthma-cases 2025-01-20T08:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-research-reveals-critical-role-of-mucus-plugging-in-severe-and-fatal-asthma-cases 2025-01-20T08:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/robust-influenza-pipeline-features-120-drug-candidates-with-novel-approaches-to-prevention-and-treatment 2025-01-20T07:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-influenza-pipeline-features-120-drug-candidates-with-novel-approaches-to-prevention-and-treatment 2025-01-20T07:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-life-advances-with-usfda-approval-for-usnoflast-phase-ii-b-clinical-trial 2025-01-20T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-life-advances-with-usfda-approval-for-usnoflast-phase-ii-b-clinical-trial 2025-01-20T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-s-fyb203-aflibercept-receives-eu-approval-as-biosimilar-to-eylea-r 2025-01-20T07:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-s-fyb203-aflibercept-receives-eu-approval-as-biosimilar-to-eylea-r 2025-01-20T07:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/cergenx-s-wave-device-receives-fda-breakthrough-designation-for-neonatal-brain-monitoring 2025-01-20T07:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cergenx-s-wave-device-receives-fda-breakthrough-designation-for-neonatal-brain-monitoring 2025-01-20T07:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/deepcure-completes-first-patient-surgery-in-u-s-clinical-trial-for-hypercure-a-laparoscopic-renal-nerve-block-device 2025-01-20T07:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepcure-completes-first-patient-surgery-in-u-s-clinical-trial-for-hypercure-a-laparoscopic-renal-nerve-block-device 2025-01-20T07:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-treating-copd-related-emphysema-through-metabolic-reprogramming 2025-01-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-treating-copd-related-emphysema-through-metabolic-reprogramming 2025-01-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/usp-launches-major-recruitment-drive-for-pharmacist-volunteers-to-shape-global-health-standards 2025-01-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usp-launches-major-recruitment-drive-for-pharmacist-volunteers-to-shape-global-health-standards 2025-01-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-targeting-pd-l1-and-4-1bb-a-new-frontier-in-follicular-lymphoma-treatment 2025-01-20T04:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-targeting-pd-l1-and-4-1bb-a-new-frontier-in-follicular-lymphoma-treatment 2025-01-20T04:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/hra-pharma-seeks-fda-approval-for-first-over-the-counter-birth-control-pill-in-the-u-s 2025-01-20T01:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hra-pharma-seeks-fda-approval-for-first-over-the-counter-birth-control-pill-in-the-u-s 2025-01-20T01:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-cancer-drug-shows-promise-in-halting-parkinson-s-disease-progression 2025-01-20T01:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-cancer-drug-shows-promise-in-halting-parkinson-s-disease-progression 2025-01-20T01:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-s-novel-breast-cancer-treatment-receives-us-approval 2025-01-20T01:30:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-s-novel-breast-cancer-treatment-receives-us-approval 2025-01-20T01:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-axsome-s-auvelity-for-major-depressive-disorder-treatment 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-axsome-s-auvelity-for-major-depressive-disorder-treatment 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-project-optimus-reshapes-early-phase-oncology-trial-design-for-better-patient-outcomes 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-project-optimus-reshapes-early-phase-oncology-trial-design-for-better-patient-outcomes 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-discontinues-amcenestrant-development-after-phase-3-first-line-breast-cancer-trial-failure 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-discontinues-amcenestrant-development-after-phase-3-first-line-breast-cancer-trial-failure 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-subcutaneous-dacogen-achieves-33-response-rate-in-myelofibrosis-patients 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promise-subcutaneous-dacogen-achieves-33-response-rate-in-myelofibrosis-patients 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/esteem-after-stroke-program-launches-phase-iii-trial-to-enhance-stroke-recovery 2025-01-19T22:31:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esteem-after-stroke-program-launches-phase-iii-trial-to-enhance-stroke-recovery 2025-01-19T22:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-brain-stimulation-technique-offers-hope-for-schizophrenia-patients 2025-01-19T22:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-brain-stimulation-technique-offers-hope-for-schizophrenia-patients 2025-01-19T22:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/serum-institute-receives-approval-for-phase-iii-clinical-trial-of-yellow-fever-vaccine 2025-01-19T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serum-institute-receives-approval-for-phase-iii-clinical-trial-of-yellow-fever-vaccine 2025-01-19T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/cdri-advances-towards-antimalarial-vaccine-with-successful-trials 2025-01-19T19:31:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdri-advances-towards-antimalarial-vaccine-with-successful-trials 2025-01-19T19:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-promise-for-personalized-vaccine-in-locally-advanced-oligometastatic-prostate-cancer 2025-01-19T19:30:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-promise-for-personalized-vaccine-in-locally-advanced-oligometastatic-prostate-cancer 2025-01-19T19:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-advances-atopic-dermatitis-treatment-with-new-clinical-trials 2025-01-19T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-advances-atopic-dermatitis-treatment-with-new-clinical-trials 2025-01-19T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/us-health-sector-advances-in-regulatory-measures-and-pharmaceutical-innovations 2025-01-19T16:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-health-sector-advances-in-regulatory-measures-and-pharmaceutical-innovations 2025-01-19T16:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-cancer-vaccines-emerging-prospects-in-immunotherapy 2025-01-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-cancer-vaccines-emerging-prospects-in-immunotherapy 2025-01-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mri-scan-innovation-cuts-bladder-cancer-treatment-wait-times-in-half-study-shows 2025-01-19T15:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mri-scan-innovation-cuts-bladder-cancer-treatment-wait-times-in-half-study-shows 2025-01-19T15:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approvals-and-clinical-trials-signal-growth-for-eli-lilly 2025-01-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approvals-and-clinical-trials-signal-growth-for-eli-lilly 2025-01-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-varying-hma-treatment-outcomes-in-mds-patients-based-on-cytogenetic-risk-profiles 2025-01-19T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-varying-hma-treatment-outcomes-in-mds-patients-based-on-cytogenetic-risk-profiles 2025-01-19T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/key-healthcare-voices-address-critical-issues-from-dementia-prevention-to-medical-freedom-movement 2025-01-19T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/key-healthcare-voices-address-critical-issues-from-dementia-prevention-to-medical-freedom-movement 2025-01-19T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-chatgpt-plus-outperforms-physician-ai-collaboration-in-diagnostic-accuracy 2025-01-19T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-chatgpt-plus-outperforms-physician-ai-collaboration-in-diagnostic-accuracy 2025-01-19T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/icam1-blockade-enhances-ischemic-muscle-reperfusion-in-diabetic-mice 2025-01-19T07:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icam1-blockade-enhances-ischemic-muscle-reperfusion-in-diabetic-mice 2025-01-19T07:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-cancer-treatment-using-oncolytic-virus-therapy 2025-01-19T07:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-cancer-treatment-using-oncolytic-virus-therapy 2025-01-19T07:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-gains-usfda-approval-for-phase-ii-b-clinical-trial-of-usnoflast-in-als-treatment 2025-01-19T07:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-gains-usfda-approval-for-phase-ii-b-clinical-trial-of-usnoflast-in-als-treatment 2025-01-19T07:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/ai-models-show-superior-accuracy-in-predicting-ovarian-cancer-surgery-outcomes 2025-01-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-models-show-superior-accuracy-in-predicting-ovarian-cancer-surgery-outcomes 2025-01-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-breakthrough-new-applications-transform-lung-cancer-diagnosis-and-treatment-pathways 2025-01-19T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-breakthrough-new-applications-transform-lung-cancer-diagnosis-and-treatment-pathways 2025-01-19T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/ugn-102-shows-promise-as-a-nonsurgical-treatment-for-low-grade-bladder-cancer 2025-01-19T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ugn-102-shows-promise-as-a-nonsurgical-treatment-for-low-grade-bladder-cancer 2025-01-19T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/btz-043-shows-promising-efficacy-in-tuberculosis-treatment-by-targeting-necrotic-granulomas 2025-01-19T01:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btz-043-shows-promising-efficacy-in-tuberculosis-treatment-by-targeting-necrotic-granulomas 2025-01-19T01:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/first-phase-of-clinical-trials-for-psilocybin-mushrooms-in-treating-methamphetamine-addiction-completed 2025-01-19T01:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-phase-of-clinical-trials-for-psilocybin-mushrooms-in-treating-methamphetamine-addiction-completed 2025-01-19T01:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-period-for-novartis-s-self-administered-ms-drug-ofatumumab 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-period-for-novartis-s-self-administered-ms-drug-ofatumumab 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-keytruda-for-second-line-lung-cancer-treatment-following-price-reduction 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-keytruda-for-second-line-lung-cancer-treatment-following-price-reduction 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-opvee-first-intranasal-nalmefene-therapy-for-opioid-overdose 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-opvee-first-intranasal-nalmefene-therapy-for-opioid-overdose 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maze-therapeutics-advances-phase-2-trials-for-chronic-kidney-disease-treatments 2025-01-18T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maze-therapeutics-advances-phase-2-trials-for-chronic-kidney-disease-treatments 2025-01-18T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/menin-inhibitors-show-promise-in-frontline-aml-treatment-highlighted-at-eha-congress 2025-01-18T22:31:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menin-inhibitors-show-promise-in-frontline-aml-treatment-highlighted-at-eha-congress 2025-01-18T22:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-seeks-approval-or-hearing-opportunity-for-new-drug-application 2025-01-18T22:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-seeks-approval-or-hearing-opportunity-for-new-drug-application 2025-01-18T22:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-14-6-billion-acquisition-of-intra-cellular-therapies-highlights-pharma-sector-moves 2025-01-18T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-14-6-billion-acquisition-of-intra-cellular-therapies-highlights-pharma-sector-moves 2025-01-18T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-lung-cancer-treatment-from-molecular-testing-to-new-therapies 2025-01-18T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-lung-cancer-treatment-from-molecular-testing-to-new-therapies 2025-01-18T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-bronchopulmonary-dysplasia-treatment-a-look-into-the-2024-pipeline 2025-01-18T19:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-bronchopulmonary-dysplasia-treatment-a-look-into-the-2024-pipeline 2025-01-18T19:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/ustekinumab-biosimilar-abp-654-shows-functional-similarity-to-stelara-in-crohn-s-disease-treatment 2025-01-18T19:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ustekinumab-biosimilar-abp-654-shows-functional-similarity-to-stelara-in-crohn-s-disease-treatment 2025-01-18T19:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/paxlovid-reduces-covid-19-hospitalization-risk-by-39-study-finds 2025-01-18T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paxlovid-reduces-covid-19-hospitalization-risk-by-39-study-finds 2025-01-18T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-pdufa-date-for-neffy-nasal-spray-and-approves-crinecerfont-for-cah-treatment 2025-01-18T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-pdufa-date-for-neffy-nasal-spray-and-approves-crinecerfont-for-cah-treatment 2025-01-18T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/extended-pelvic-lymph-node-dissection-shows-superior-metastasis-control-in-prostate-cancer-patients 2025-01-18T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-pelvic-lymph-node-dissection-shows-superior-metastasis-control-in-prostate-cancer-patients 2025-01-18T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-promise-in-restoring-brain-activity-post-stroke 2025-01-18T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapy-shows-promise-in-restoring-brain-activity-post-stroke 2025-01-18T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-extends-progression-free-survival-in-unresectable-liver-cancer 2025-01-18T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapy-extends-progression-free-survival-in-unresectable-liver-cancer 2025-01-18T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-zeiss-mel-90-excimer-laser-and-accepts-revised-snda-for-izervay 2025-01-18T16:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-zeiss-mel-90-excimer-laser-and-accepts-revised-snda-for-izervay 2025-01-18T16:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-showcases-heart-rhythm-technologies-at-af-symposium-2025 2025-01-18T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-showcases-heart-rhythm-technologies-at-af-symposium-2025 2025-01-18T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/pioneering-patient-begins-revolutionary-gene-therapy-journey-for-sickle-cell-disease 2025-01-18T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneering-patient-begins-revolutionary-gene-therapy-journey-for-sickle-cell-disease 2025-01-18T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-secures-590m-u-s-award-for-bird-flu-vaccine-development 2025-01-18T11:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-secures-590m-u-s-award-for-bird-flu-vaccine-development 2025-01-18T11:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/fermion-and-simcere-partner-to-develop-china-s-first-sstr4-agonist-for-pain-management 2025-01-18T11:01:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fermion-and-simcere-partner-to-develop-china-s-first-sstr4-agonist-for-pain-management 2025-01-18T11:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/kymera-therapeutics-advances-kt-621-into-patient-studies-amid-development-uncertainties 2025-01-18T10:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kymera-therapeutics-advances-kt-621-into-patient-studies-amid-development-uncertainties 2025-01-18T10:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-rare-liver-cancer-treatment-clinical-trial-begins 2025-01-18T10:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-rare-liver-cancer-treatment-clinical-trial-begins 2025-01-18T10:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-high-comorbidity-rates-between-cluster-headache-fibromyalgia-and-migraine 2025-01-18T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-high-comorbidity-rates-between-cluster-headache-fibromyalgia-and-migraine 2025-01-18T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sacituzumab-govitecan-shows-promise-in-heavily-pretreated-hr-her2-breast-cancer-patients 2025-01-18T08:01:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sacituzumab-govitecan-shows-promise-in-heavily-pretreated-hr-her2-breast-cancer-patients 2025-01-18T08:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/retinal-imaging-shows-promise-as-novel-stroke-risk-prediction-tool-uk-study-finds 2025-01-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinal-imaging-shows-promise-as-novel-stroke-risk-prediction-tool-uk-study-finds 2025-01-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/poor-outcomes-persist-in-secondary-aml-patients-previously-treated-with-hypomethylating-agents 2025-01-18T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poor-outcomes-persist-in-secondary-aml-patients-previously-treated-with-hypomethylating-agents 2025-01-18T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiovascular-polypill-shows-cost-effectiveness-for-low-income-and-black-populations 2025-01-18T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiovascular-polypill-shows-cost-effectiveness-for-low-income-and-black-populations 2025-01-18T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/peng-block-vs-caudal-block-for-pediatric-hip-surgery-a-comparative-study-on-analgesia-efficacy 2025-01-18T04:30:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peng-block-vs-caudal-block-for-pediatric-hip-surgery-a-comparative-study-on-analgesia-efficacy 2025-01-18T04:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approvals-and-clinical-trials-a-look-into-the-latest-pharmaceutical-developments 2025-01-18T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approvals-and-clinical-trials-a-look-into-the-latest-pharmaceutical-developments 2025-01-18T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medibeacon-r-transdermal-gfr-system-for-kidney-function-assessment 2025-01-18T01:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medibeacon-r-transdermal-gfr-system-for-kidney-function-assessment 2025-01-18T01:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-igg-degrading-enzyme-kj103-shows-promising-safety-and-efficacy-in-phase-i-trials 2025-01-18T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-igg-degrading-enzyme-kj103-shows-promising-safety-and-efficacy-in-phase-i-trials 2025-01-18T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionizing-cancer-treatment-the-rise-of-functional-precision-medicine 2025-01-18T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionizing-cancer-treatment-the-rise-of-functional-precision-medicine 2025-01-18T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-spevigo-first-ever-treatment-for-generalized-pustular-psoriasis-flares 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-spevigo-first-ever-treatment-for-generalized-pustular-psoriasis-flares 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-acquires-atopic-dermatitis-drug-nm26-in-1-25-billion-deal-with-numab-therapeutics 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-acquires-atopic-dermatitis-drug-nm26-in-1-25-billion-deal-with-numab-therapeutics 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-start-programme-selects-first-rare-disease-therapies-for-accelerated-development 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-start-programme-selects-first-rare-disease-therapies-for-accelerated-development 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avapritinib-shows-promising-improvements-in-bone-density-for-advanced-systemic-mastocytosis-patients 2025-01-17T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avapritinib-shows-promising-improvements-in-bone-density-for-advanced-systemic-mastocytosis-patients 2025-01-17T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-high-dose-wegovy-shows-promising-weight-loss-results-fda-approves-expanded-uses-for-amgen-and-astrazeneca-drugs 2025-01-17T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-high-dose-wegovy-shows-promising-weight-loss-results-fda-approves-expanded-uses-for-amgen-and-astrazeneca-drugs 2025-01-17T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-high-dose-semaglutide-shows-promising-weight-loss-results-in-phase-3b-trial 2025-01-17T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-high-dose-semaglutide-shows-promising-weight-loss-results-in-phase-3b-trial 2025-01-17T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-amgen-s-innovative-treatment-for-pretreated-colorectal-cancer-with-specific-mutation 2025-01-17T20:01:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-amgen-s-innovative-treatment-for-pretreated-colorectal-cancer-with-specific-mutation 2025-01-17T20:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-once-weekly-insulin-icodec-shows-promise-in-phase-3-trials 2025-01-17T20:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-once-weekly-insulin-icodec-shows-promise-in-phase-3-trials 2025-01-17T20:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/fulvestrant-shows-comparable-overall-survival-to-anastrozole-in-advanced-breast-cancer-study 2025-01-17T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulvestrant-shows-comparable-overall-survival-to-anastrozole-in-advanced-breast-cancer-study 2025-01-17T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/2024-advances-in-lipid-management-a-year-of-progress-and-setbacks 2025-01-17T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2024-advances-in-lipid-management-a-year-of-progress-and-setbacks 2025-01-17T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/amrith-noni-artho-plus-completes-successful-clinical-trials-marking-a-breakthrough-in-ayurvedic-medicine 2025-01-17T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amrith-noni-artho-plus-completes-successful-clinical-trials-marking-a-breakthrough-in-ayurvedic-medicine 2025-01-17T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drugs-in-oncology-hematology-and-neurology-set-to-transform-treatment-in-2025 2025-01-17T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-drugs-in-oncology-hematology-and-neurology-set-to-transform-treatment-in-2025 2025-01-17T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-7-2-mg-shows-superior-weight-loss-in-step-up-trial 2025-01-17T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-7-2-mg-shows-superior-weight-loss-in-step-up-trial 2025-01-17T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advances-early-detection-of-kidney-injury-with-new-urine-biomarker-panel 2025-01-17T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advances-early-detection-of-kidney-injury-with-new-urine-biomarker-panel 2025-01-17T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/art26-12-advances-in-clinical-trials-for-neuropathic-pain-treatment 2025-01-17T19:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/art26-12-advances-in-clinical-trials-for-neuropathic-pain-treatment 2025-01-17T19:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/luke-arm-neuroprosthesis-enters-new-phase-with-first-home-use-clinical-trial 2025-01-17T19:30:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luke-arm-neuroprosthesis-enters-new-phase-with-first-home-use-clinical-trial 2025-01-17T19:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-higher-dose-wegovy-shows-over-20-weight-loss-in-late-stage-trial 2025-01-17T17:01:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-higher-dose-wegovy-shows-over-20-weight-loss-in-late-stage-trial 2025-01-17T17:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/topspin-study-reveals-effective-single-pill-combinations-for-hypertension-in-south-asians 2025-01-17T16:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topspin-study-reveals-effective-single-pill-combinations-for-hypertension-in-south-asians 2025-01-17T16:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/tucatinib-and-trastuzumab-show-promise-in-her2-mutated-metastatic-breast-cancer 2025-01-17T16:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tucatinib-and-trastuzumab-show-promise-in-her2-mutated-metastatic-breast-cancer 2025-01-17T16:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-fasenra-poised-to-transform-copd-treatment-with-promising-phase-iii-data 2025-01-17T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-fasenra-poised-to-transform-copd-treatment-with-promising-phase-iii-data 2025-01-17T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-shows-promise-for-rheumatoid-arthritis-treatment 2025-01-17T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vagus-nerve-stimulation-shows-promise-for-rheumatoid-arthritis-treatment 2025-01-17T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-of-two-new-vaccines-against-bluetongue-disease 2025-01-17T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-of-two-new-vaccines-against-bluetongue-disease 2025-01-17T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-receives-approval-in-australia-for-nasopharyngeal-carcinoma-treatment 2025-01-17T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toripalimab-receives-approval-in-australia-for-nasopharyngeal-carcinoma-treatment 2025-01-17T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-foundationone-r-cdx-as-companion-diagnostic-for-pediatric-brain-tumor-treatment 2025-01-17T16:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-foundationone-r-cdx-as-companion-diagnostic-for-pediatric-brain-tumor-treatment 2025-01-17T16:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-therapeutics-announces-promising-phase-ia-trial-results-for-ava6000-in-salivary-gland-cancer 2025-01-17T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-therapeutics-announces-promising-phase-ia-trial-results-for-ava6000-in-salivary-gland-cancer 2025-01-17T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-medicine-advances-in-2024-a-year-of-groundbreaking-clinical-trials-and-research 2025-01-17T16:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-medicine-advances-in-2024-a-year-of-groundbreaking-clinical-trials-and-research 2025-01-17T16:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/palisade-bio-advances-to-mad-cohorts-in-phase-ia-b-trial-for-ulcerative-colitis-therapy 2025-01-17T16:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palisade-bio-advances-to-mad-cohorts-in-phase-ia-b-trial-for-ulcerative-colitis-therapy 2025-01-17T16:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/new-fusion-protein-therapy-shows-promise-for-treating-rare-skin-lymphomas 2025-01-17T16:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-fusion-protein-therapy-shows-promise-for-treating-rare-skin-lymphomas 2025-01-17T16:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/major-insurers-and-pbms-control-34-of-medicare-part-d-pharmacy-spending-study-reveals 2025-01-17T15:00:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-insurers-and-pbms-control-34-of-medicare-part-d-pharmacy-spending-study-reveals 2025-01-17T15:00:27+00:00 hourly 0.9 https://trial.medpath.com/news/novel-glycan-based-approach-shows-promise-in-enhancing-car-t-cell-therapy-efficacy 2025-01-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-glycan-based-approach-shows-promise-in-enhancing-car-t-cell-therapy-efficacy 2025-01-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/qelbree-r-label-update-includes-new-pharmacodynamic-data-and-breastfeeding-information 2025-01-17T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qelbree-r-label-update-includes-new-pharmacodynamic-data-and-breastfeeding-information 2025-01-17T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/illuccix-r-receives-european-approval-for-prostate-cancer-imaging 2025-01-17T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illuccix-r-receives-european-approval-for-prostate-cancer-imaging 2025-01-17T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/perioperative-chemotherapy-shows-survival-benefit-in-locoregional-small-cell-bladder-cancer 2025-01-17T13:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perioperative-chemotherapy-shows-survival-benefit-in-locoregional-small-cell-bladder-cancer 2025-01-17T13:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-lumakras-receives-fda-approval-for-colorectal-cancer-treatment 2025-01-17T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-lumakras-receives-fda-approval-for-colorectal-cancer-treatment 2025-01-17T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-s-karxt-for-schizophrenia-treatment-accepted-for-review-in-china 2025-01-17T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-s-karxt-for-schizophrenia-treatment-accepted-for-review-in-china 2025-01-17T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/early-biomarkers-in-huntington-s-disease-a-path-to-pre-symptomatic-treatment 2025-01-17T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-biomarkers-in-huntington-s-disease-a-path-to-pre-symptomatic-treatment 2025-01-17T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/optilume-drug-coated-balloon-demonstrates-long-term-efficacy-in-treating-urethral-strictures 2025-01-17T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optilume-drug-coated-balloon-demonstrates-long-term-efficacy-in-treating-urethral-strictures 2025-01-17T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/gt-medical-raises-37m-series-d-to-advance-brain-tumor-radiotherapy-innovation 2025-01-17T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gt-medical-raises-37m-series-d-to-advance-brain-tumor-radiotherapy-innovation 2025-01-17T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomerica-s-fortel-psa-test-receives-mohap-approval-for-early-prostate-cancer-detection 2025-01-17T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomerica-s-fortel-psa-test-receives-mohap-approval-for-early-prostate-cancer-detection 2025-01-17T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/pooled-safety-analysis-highlights-tolerability-of-trifluridine-tipiracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2025-01-17T10:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pooled-safety-analysis-highlights-tolerability-of-trifluridine-tipiracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2025-01-17T10:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-confirms-safety-of-tnf-inhibitors-for-rheumatoid-arthritis-interstitial-lung-disease 2025-01-17T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-confirms-safety-of-tnf-inhibitors-for-rheumatoid-arthritis-interstitial-lung-disease 2025-01-17T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/nelonemdaz-shows-promise-in-treating-out-of-hospital-cardiac-arrest-patients 2025-01-17T10:31:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nelonemdaz-shows-promise-in-treating-out-of-hospital-cardiac-arrest-patients 2025-01-17T10:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-redefine-1-trial-results-lead-to-mixed-analyst-outlook-despite-strong-financial-performance 2025-01-17T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-redefine-1-trial-results-lead-to-mixed-analyst-outlook-despite-strong-financial-performance 2025-01-17T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-dime-collaborate-to-validate-novel-digital-clinical-measures 2025-01-17T07:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-dime-collaborate-to-validate-novel-digital-clinical-measures 2025-01-17T07:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-treatment-strategy-shows-promise-for-dedifferentiated-liposarcoma 2025-01-17T07:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-treatment-strategy-shows-promise-for-dedifferentiated-liposarcoma 2025-01-17T07:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/senaparib-receives-nmpa-approval-for-first-line-maintenance-therapy-in-advanced-ovarian-cancer 2025-01-17T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senaparib-receives-nmpa-approval-for-first-line-maintenance-therapy-in-advanced-ovarian-cancer 2025-01-17T07:31:22+00:00 hourly 0.9